host pathogen interactions in helicobacter pylori related gastric … · 2017-04-29 · h. pylori...

Magdalena Chmiela, Weronika Gonciarz, ��ana �ll��hi, ��ana �ll��hi,��ana �ll��hi, Department of Immunology and Infectious Biology, Institute of Microbiology, Biotechnology and Immunology, Faculty of Biology and Environmental Protection, University of Lodz, Banacha, 90-237 Lodz, Poland PolandPoland

Zuzanna Karwowska, Paweł Stączek, Department of Genetics of Bacteria, Institute of Microbiology, Biotechnology and Immunology, Faculty of Biology and Environmental Protection, University of Lodz, Banacha, 90-237 Lodz, Poland

Author contributions: Chmiela M designed, �rote and designed, �rote anddesigned, �rote and supervised the manuscript; Kar�o�ska Z, Gonciarz W� and andand Allushi B� ��si�� h� ��us��i�� si�� h� ��us��i�� si�� h� ��us��i�� pre-revie�ed the manuscript.

Conflict-of-interest statement: No potential conflicts of interest.

Open-Access: This article is an open-access article �hich �as selected by an in-house editor and fully peer-revie�ed by external revie�ers. It is distributed in accordance �ith the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, �hich permits others to distribute, remix, adapt, build upon this �ork non-commercially, and license their derivative �orks on different terms, provided the original �ork is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/

Manuscript source: Invited manuscript

Correspondence to: Magdalena Chmiela, PhD, Pro�e��or, Pro�e��or,Pro�e��or,, Department of Immunology and Infectious Biology, Institute of Microbiology, Biotechnology and Immunology, Faculty of Biology and Environmental Protection, University of Lodz, Banacha 12/16, 90-237 Lodz, Poland. [email protected]: +48-42-6354186Fax: +48-42-6655818

Received: August 24, 2016Peer-review started: August 25, 2016First decision: September 12, 2016Revised: October 26, 2016Accepted: February 16, 2017

Article in press: February 17, 2017Published online:: March 7, 2017

AbstractHelicobacter pylori (H. pylori ), di�co�ered in ��, i� a, di�co�ered in ��, i� a microaerophilic, spiral-shaped gram-negative bacterium that is able to colonize the human stomach. Nearly half of the world’s population is infected by this pathogen. Its ability to induce gastritis, peptic ulcers, gastric cancer and mucosa-associated lymphoid tissue lymphoma has been confirmed. The susceptibility of an individual to these clinical outcomes is multifactorial and depends on H. pylori virulence, environmental factors, the genetic susceptibility of the host and the reactivity of the host immune system. Despite the host immune response, H. pylori infection can be difficult to eradicate. H. pylori is categorized as a group Ⅰ carcinogen since this bacterium is responsible for the highest rate of cancer-related deaths worldwide. Early detection of cancer can be lifesaving. The 5-year survival rate for gastric cancer patients diagnosed in the early stages is nearly 90%. Gastric cancer is asymptomatic in the early stages but always progresses over time and begins to cause symptoms when untreated. In 97% of stomach cancer cases, cancer cells metastasize to other organs. H. pylori infection is responsible for nearly 60% of the intestinal-type gastric cancer cases but also influences the development of diffuse gastric cancer. The host genetic susceptibility depends on polymorphisms of genes in�ol�ed in H. pylori -related inflammation and the cytokine response of gastric epithelial and immune cells. H. pylori strains differ in their ability to induce a deleterious inflammatory response. H. pylori -driven cytokines accelerate the inflammatory response and promote malignancy. Chronic H. pylori infection induces genetic instability in gastric epithelial cells and affects the DNA damage repair systems. Therefore, H. pylori infection should always be considered a pro-cancerous factor.

Submit a Manuscript: http://www.wjgnet.com/esps/

DOI: 10.3748/wjg.v23.i9.1521

1521 March 7, 2017|Volume 23|Issue 9|WJG|www.wjgnet.com

World J Gastroenterol 2017 March 7; 23(9): 1521-1540

ISSN 1007-9327 (print) ISSN 2219-2840 (online)

FRONTIER

Host pathogen interactions in Helicobacter pylori related gastric cancer

Magdalena Chmiela, Zuzanna Karwowska, Weronika Gonciarz, Bujana Allushi, Paweł Stączek

Key words: Helicobacter pylori ;� host susceptibility��;� Carcinogene�i�;�;� �acterial diversity

© The Author(s) 2017. Published by Baishideng Publishing Group Inc. All rights reserved.

Core tip: In ��4 Helicobacter pylori (H. pylori ) �a��a� classified by the International Agency for Research of Cancer as a class I human carcinogen for gastric cancer. Nearly 60% of the intestinal type gastric cancers are associated with H. pylori infections. Cancer risk rises if strain possess virulence factors: CagA, �acA and possess virulence factors: CagA, �acA andpossess virulence factors: CagA, �acA and BabA. These bacteria promotes gastric carcinogenesis by increased DNA damage, impairment of repair pro-cesses, induction of mitochondrial DNA and genomic mutations. Nearly 98% of mucosa associated lymphoid tissue lymphomas are H. pylori dependent. We discuss correlation between H. pylori and gastric cancer in the light of bacterial and host genetic variability.

Ch�i�l� M�� K��s�� Z�� i�� Allushi B�� i�� Allushi B�� i�� Allushi B�� Allushi B�� Allushi B�� Host pathogen interactions in Helicobacter pylori related gastric cancer. World J Gastroenterol 2017; 23(9): 1521-1540 Available1521-1540 Available from: URL: http://��.�jgnet.com/1007-9327/full/v23/i9/1521.htm DOI: http://dx.doi.org/10.3748/�jg.v23.i9.1521

BIOGRAPHYWith a master degree on biology, microbiology as specialty, upon her PhD on Immunology in 1991, Magdalena Chmiela (Figure 1) was nominated in 2005 on the position of permanent Professor (medical microbiology, immunology) at the Faculty of Biology and Environmental Protection, University of Lodz, Poland. She is currently head of the Department of Immunology and Infectious Biology at the Institute of Microbiology, Biotechnology and Immunology. For more than 30 years her research concerns the immunology of infectious diseases including: immune processes reg-ulating host-pathogen interactions, bacterial virulence factors that determine the course of infections, the use of microorganisms in the design and manufacture of biological components for potential therapeutic use, prevention and diagnostic. With particular attention she leads research on Helicobacter pylori (H. pylori) infec-tions, which are responsible for gastric and duodenal ulcers and even stomach cancers. Work on this subject she began in 1992, being a member of the research team at the Department of Medical Microbiology Lund University in Sweden. She also conducts research about Campylobacter sp. With her experience she pub-lished numerous papers, review articles, coordinated and participated in a number of research projects and evaluated them as an expert. She is a member of the Scientific Council of the Institute of Medical Biology,

Polish Academy of Sciences; editorial board member of the World Journal of Gastroenterol (2014-2017); member of American Society for Microbiology and Polish Society for Microbiology. She shares her profes-sional activity between research work and academic professor activity.

INTRODUCTIONThe stomach is considered a hostile environment for microorganisms. The acidic pH and peristaltic movements of the stomach prevent colonization by pathogens. In 1982, Barry Marshall and Robin Warren revolutionized the concept of gastroduodenal diseases by the discovery of H. pylori and by proving that these gram-negative bacteria cause infections in humans due to colonization of the stomach. If the pathogen is not eradicated by the immune system of the host, it stimulates the development of chronic inflamma-tion. The pathogen is a major agent in gastritis and peptic ulcers (PU), which were previously thought to be caused by stress and diet. Now it is known that H. pylori is also involved in the development of gastric cancer (GC).

The aim of this review is to present a brief over-view of how H. pylori infection impacts tumorigenesis. Gastric adenocarcinoma has the second highest mortality rate in the world. Nearly half of the world’s population is infected by H. pylori. Various structural components and soluble factors of H. pylori enable these microbes to colonize the stomach and induce an inflammatory response. Close contact with an infected person facilitates transmission of the pathogen by an oral-oral or oral-fecal route. Clinical outcomes that are linked with H. pylori infection include chronic inflam-mation of the gastric mucosa, gastric and duodenal ulcers (DUs) and GC. Although a correlation between the pathogen and carcinogenesis has been estab-lished, more studies are needed to understand specific mechanisms, the diversity of infectious agents, and the genetic susceptibility and immune profile of the host.


Chmiela M et al. H. pylori and gastric carcinogenesis

Figure 1 ��g��e�� ie�� g��e�� ie�� P�D�� Professor�� Dep�rt�e�t of I��u�o�ogy �� I�fectious Bio�ogy�� U�iversity of Lo�z�� F�cu�ty of Bio�ogy �� E�viro��e�t�� Protectio�� Lo�z 90237�� Po��

MICROBIOLOGICAL ASPECTS OF H. pyloriPrimary bacteriological featuresH. pylori is considered the most prevalent human pathogen, and its evolution appears to have been very effective since the bacterium has developed several strategies to cause infection[1]. H. pylori had escaped the attention of researchers until Barry Marshall and Robin Warren published data on the curved bacterium that colonizes the human stomach[2]. Substantial alter-ations have been made concerning the disease causa-tion after intensive studies on H. pylori[3]. This patho-genic microorganism was first named Campylobacter pyloridis. It was only after facing important genotypic and phenotypic dissimilarities with other bacteria in the Campylobacter genus that a decision was made to create a new genus: Helicobacter. It is now commonly accepted that this gram-negative, microaerophilic, flag-ellated microorganism induces chronic active gastritis (asymptomatic or symptomatic), peptic ulcer disease and duodenal ulcers in humans; it is also related to GC[4,5].

Virulence factorsThe colonization of epithelial cells of the stomach by H. pylori begins with the binding of these bacteria with epithelial cell receptors. Then the bacteria escape of host defense mechanisms, induce inflammatory responses, which allow acquisition of nutrients for suc-cessful replication[6]. Majour H. pylori adhesins belong to the family of proteins localized in outer membrain of bacterial cells. The blood group antigen-binding adhe-sin A (BabA) and sialic acid binding adhesin (SabA) are the most important adhesisns of H. pylori[7-11]. Also other OMPs, such as HopZ and OipA play a role of adhesins. It has been shown that OipA induces more intensive inflammatory response due to neutrophil infiltration and promotes the development of duodenal ulcer and gastric cancer[7]. Urease elevates the acidic pH of the stomach and unipolar flagella facilitate penetration of mucus[3]. The ability to glycosylate host cholesterol is crucial for the virulence and antibiotic resistance of H. pylori[12]. H. pylori lipopolysaccharide (LPS), due to its structural features, induces a poor immune response and helps the bacteria develop into a chronic infection[13-18]. H. pylori LPS may carry various human Lewis (Le)-like antigens, which may (Le)-like antigens, which may(Le)-like antigens, which may play a role in autoimmunity. Specifically, LeX deter-minants in O antigen of H. pylori LPS may facilitate the adherence of bacterial cells to gastric epithelium. This process involves the binding of gastric receptor β-galactoside-binding lectin (galectin-3)[19-21]. The H. pylori outer membrane vesicles are an alternative vehicle for the distribution of bacterial virulence fac-tors and antigens[22,23]. The major virulence factors of H. pylori are encoded by genes within the pathogenic-ity island (PAI). The cytotoxin-associated gene A

(CagA) protein is one of the most important H. pylori virulence factors. CagA is encoded by the cagA gene and translocated to the host gastric epithelial cells through a type Ⅳ secretion system[24-28]. A correlation between the presence of CagA in H. pylori strains and more severe inflammatory responses and a higher risk of gastric cancer has been shown[26-29]. Other virulence proteins include vacuolating cytotoxin A (VacA), BabA and SabA[9,10,30,31]. VacA induces vacuolation of gastric epithelial cells as well as cell apoptosis and disrupts the gastric epithelial barrier function[28]. BabA and SabA are adhesins, and SabA is essential for nonopsonic activation of human neutrophils[9,7]. BabA interacts with the Leb blood group antigen on epithelial cells, and the babA2 gene is associated with DU and GC[10]. SabA is known to bind sialyl-dimeric-Lex[8], as well as sialylated Lea[9]. Malignant transformation is linked with pronounced expression of Lea, sialylated Lea and sialyl-dimeric-Lex, however, knowledge about the role of SabA in tumorigenesis is still limited[9].

Immune system evasion strategiesBlaser (1993) proposed a model in which both the host and the parasite adapt to downregulate the inflam-matory response to promote survival and to continue colonization of the niche[32-34]. Pathogen-associated molecular patterns (PAMPs) are various molecules of pathogenic microorganisms that in normal conditions are recognized by pattern recognition receptors (PRRs) resulting in triggering of the inflammatory response. H. pylori possess several mechanisms that prevent their recognition via Toll-like receptors (TLRs): (1)(1)) changing and rearranging LPS and flagellin; and (2)and (2)) molecular mimicry between human Lewis and ABO blood group antigens and bacterial compounds, which confuses immune cells and prevents recognition of the pathogen[21,35,36]. It has been shown that the H. pylori flagellin is not detected by specific PRRs, and it does not stimulate the production of interleukin (IL)-8. As a result, chemotaxis of immune cells to the site of infec-tion and phagocytosis of H. pylori are diminished[37].

Prevention of phagocytic killing has been dem-onstrated to be more efficient due to delayed polymerization of actin and inhibition of phagosome and phagolysosome formation[28,38]. The primary host immune response mechanisms, such as phagocy-tosis and natural killer (NK) cell activity, have been found to be downregulated by H. pylori LPS[17,18,39,40]. Adaptive immunity is also targeted by H. pylori com-pounds[1,15,41,42]. They affect antigen presentation by inducing macrophage apoptosis and by diminishing dendritic cell (DC) and macrophage maturation[18,43]. The expression of programmed death 1 ligand-1 (B7-H1 integrin) on gastric epithelial cells modu-lates T cell trafficking during H. pylori infection. The function of B7-H1 is to inhibit effector T lympho-cytes and stimulate DCs to increase secretion of the anti-inflammatory cytokine IL-10. B7-H1, by join-



ing programmed cell death receptor 1 on the surface of T cells, inhibits proliferation and differentiation of naïve T lymphocytes and promotes the activity of regulatory cells, which downregulates effector T lymphocytes. Regulatory T cells, which possess the ability to suppress anti-tumor and anti-infectious responses are identified on the basis of cluster differ-entiation (CD) markers and forkhead box P3 (FOXP3) as CD4(+)CD25(high) and FOXP3-positive. Enarsson et al[44] studied regulatory T lymphocytes in stom-studied regulatory T lymphocytes in stom-ach tissue in H. pylori positive patients in terms of their activity and the expression of homing recep-tors. The increased number of regulatory T cells has been detected in gastric tissue of patients with gastric tumor vs non-tumor patients. Regulatory T lympho-cytes suppressed H. pylori-induced T cell proliferation and interferon (IFN)-γ production. Furthermore, theseproduction. Furthermore, these regulatory T lymphocytes expressed increased levels of l-selectin and C-C chemokine receptor 4, than the cells lacking regulatory function. These receptors may be involved in the infiltration of regulatory lympho-cytes specific to H. pylori antigens present in gastric tissue in H. pylori infected individuals. However, low activity of T regulatory cells may promote the maintenance of the infection and potentially the propagation of tumor cells[45]. The suppression of the activity of memory T lymphocytes, which enables a chronic infection, has been confirmed by other study groups[45-48]. The role of regulatory T lymphocytes can be related to the inhibition of the inflammatory response driven by IL-17 delivered by T helper (Th) 17 lymphocytes[49-52]2]].

Different studies have shown that humoral response against H. pylori is less essential in the defense against this pathogen.The study on mice lacking B lymphocytes showed that gastritis, which developed in animals immunized with prophylactic vaccine was not related to B-cells. The response was similar to that of non immunized mice[53,54]. It can be concluded that antibody responses may not promote protection. However, a correlation between high levels of serum anti-H. pylori IgG and IgA and the development of gastritis, duodenal ulcers and gastric cancer has been shown[1].

PATHOGENIC ACTIVITY OF H. pylori IN THE HOST ORGANISMEpidemiologyThere is an inverse association between socioeco-nomic status and the rate of infection[54]. Analyses have been conducted to test whether animals or water can be sources of H. pylori infection. Only a few of the animal case studies showed positive results, leading to the conclusion that the infection cycle might include humans, the environment and animals. However, the water case studies failed to support the hypothesis that water is an environmental reservoir


of H. pylori[55]. The principal method of spreading H. pylori infection is intrapersonal transmission. This has been confirmed by the high percentage of infec-tions that are spread between close relatives, especially between a mother and her children[56].

Clinical complicationsThe clinical aspects of H. pylori infection vary from gastritis and peptic ulcers to gastric cancer. It has been suggested that the pathogen might also be associated with several extragastric diseases. Shortly after initial infection of the host, acute gastritis develops that is related to hypochlorhydria and to the loss of acid secretion. Acute gastritis does not last long, but in the majority of subjects, the immune response is unable to eradicate the infection, and as a consequence, chronic gastritis is induced. According to various studies, half of the world’s population may suffer from chronic gastritis, which can be manifested in one of three forms: (1) antral-predominant; (2) corpus-(1) antral-predominant; (2) corpus-) antral-predominant; (2) corpus-; (2) corpus- (2) corpus-(2) corpus-) corpus-predominant; and (3) diffuse. These pathologies lead; and (3) diffuse. These pathologies lead and (3) diffuse. These pathologies lead(3) diffuse. These pathologies lead) diffuse. These pathologies lead to different consequences, which they favorably induce. Specifically, antral-predominant gastritis promotes duodenal ulcers whereas corpus-predominant gastritis promotes gastric ulcers, which may lead to metaplasia and adenocarcinoma; and diffuse gastritis is related to reduced acid secretion in the stomach[57-59]. In general H. pylori infections are responsible for 95% of duodenal ulcer cases and 85% of gastric ulcers. Nonsteroidal anti-inflammatory drugs are responsible for the cases that are not related to pathogen-induced inflammation[3]. Extragastric diseases potentially related to H. pylori include idiopathic thrombocytopenic purpura and iron deficiency anemia[60-66]. The influence of pathogen-induced inflammation has also been con-sidered in several dermatological disorders, diabetes and cardiovascular, and pulmonary disease[67-76]. The connection between H. pylori-induced inflammation and cardiovascular disease was reported in 1994 by Mendall et al[77], and this work was then followed by many other studies[78-86]. However, the association between H. pylori infection and extragastric disease remains unclear. Therefore, the recommendation for H. pylori treatment is irrelevant[3]. According to recent data, H. pylori infection might facilitate the onset of hepatic encephalopathy[87]. The theory of H. pylori influence in diabetes is very recent. Speci-fically, CagA+ strains are thought to enhance the risk of diabetic complications[88-92]. There is no doubt about the beneficial effect of the infection against endoscopic gastroesophageal reflux disease[93-95]. However, H. pylori infection may potentially prevent the development of adenocarcinoma of esophagus[96]. Based on a case-control study, infection with H. pylori, particularly the CagA+ strain, has been found to be inversely associated with Barrett’s esophagus[97]. H. pylori infection likely has a beneficial role in matura-tion of the immune system in the early stages of life


and prevents asthma development in the future[98-103]. The most dangerous clinical aspects of H. pylori are gastric cancer[29,48,104-108] and mucosa-associated lymphoid tissue (MALT) lymphoma[109-111]. The role of H. pylori in destruction of epithelial cell nuclei and mitochondrial DNA has been confirmed. This mutagenic effect is in part related to downregula-tion of the expression, as well as the activity, of DNA repair pathways. Machado et al[112] demonstrateddemonstrated that infection of gastric adenocarcinoma cells with H. pylori induced mutations in mitochondrial DNA and decreased the DNA content. The increased frequency of mutations in mitochondrial DNA was related to diminished effectiveness of DNA repair mechanisms. They showed that apurinic/apyrimidinic (AP) endonuclease-1 and Y-box-binding protein 1 mitochondrial base excision repair and mismatch repair systems are involved in DNA repair during H. pylori infection[112].

ROLE OF H. pylori IN TUMORIGENESISFrom carcinogenesis to gastric cancerAccumulation of numerous mutations in DNA of gas-tric epithelial cells, resulting in activation of oncogens or inactivation of tumor suppressor genes promotes the development of gastric cancer[113,114].

Nearly 120 years ago, the first gastrectomy was performed to treat gastric cancer. Since then, tumor resection in the stomach has been the standard method of treatment. On average, only 15%-20% of patients live up to 5 years after resection. Patients diagnosed in the early stages of gastric cancer have a 5-year survival of nearly 90%[115,116]. Cancer in early stages can be surgically curable because of its local development. The advancement of gastric cancer is directly proportional to the involvement of regional and non-regional lymphoid nodes, as well as organ metastasis. If the cancer is scattered throughout the body, surgical methods that treat local cancer are not effective. In these cases, implementation of additional cytostatic and hormonal treatment is necessary. Approximately 97% of gastric cancer cases are linked with metastasis. Sarcomas and non-Hodgkin’s lym-phoma rarely occur. Every year, 670000 new cancer cases are registered around the world. Gastric cancer is two-times more frequent in men than in women. It usually occurs between the ages of 50 and 70, but lately, it is increasingly being detected in young people. Gastric cancer grows by contiguous extension (direct infiltration) to other organs, such as the pancreas, liver, transverse colon, duodenum and esophagus, as well as through the peritoneum to the recto-uterine Douglas pouch. Metastatic cancer spreads through the ovaries and lymphatic or blood vessels[115-117].

In 1965, Lauren described two histologically different stomach adenocarcinomas - diffuse and intestinal[118]8]]. The diffuse type is considered an endemic cancer

type. Diffuse adenocarcinoma affects mostly women and younger populations. The typical development area of the endemic type is the proximal portion of the stomach. It often coexists with the A blood group, which suggests a possible genetic basis for tumor formation. The intestinal type is related to preneo-plastic changes, such as chronic atrophic gastritis and intestinal metaplasia of mucous membranes. This type concerns tumors in the peripheral part of the stomach. Intestinal adenocarcinoma is an epidemic type of cancer because it occurs in regions with a high risk of gastric cancer morbidity. It affects mostly men and older populations[116,118].

Gastric cancer as a consequence of H. pylori infectionThe discovery of H. pylori confirmed that the etiology of chronic gastritis and the “precancerous cascade” resulting in cancer formation is associated with H. pylori infection[119]. Now, it is commonly accepted that H. pylori is a gastric cancer carcinogen since in 1994, H. pylori has been included by the International Agency for Research on Cancer to class Ⅰ carcino-gens[120]. Nearly 60% of intestinal-type gastric cancers are associated with such infections[121,122]. Over years, patients develop acute and then atrophic gastritis, followed by intestinal metaplasia, dysplasia and carcinoma. H. pylori infection also stimulates the development of diffuse type adenocarcinoma by causing pangastritis and rugal hyperplastic gastri-tis[123]. Cancer risk rises if virulence factors, such as CagA, VacA and BabA, are present in the H. pylori strain[28,29,124]. However, infection with H. pylori CagA+ strains may potentially diminish the risk of adenocar-cinoma of esophagus and gastric cardia[125]. There is an increasing interest on the role H. pylori oipA posi-tive strains in the pathogenesis of gastric ulcer and cancer. When oipA is present, the functional “on” sta-tus of this gene was associated with increased risk of these diseases compared with gastritis and functional dyspepsia controls[7].

Environmental factors also stimulate the initiation of atrophic changes and decrease the secretion of hydrochloric acid. Elevated pH of the gastric juice facilitates bacterial colonization, causing further dam-age to epithelial cells. In addition, nitrates in foods are precursors of nitrosamines, which cause intestinal metaplasia and dysplasia (abnormal epithelial dif-ferentiation, in the form of improper development of the cells with the loss of ability to differentiate)[126,127].

Machado et al[128] have proposed three possible mechanisms of initiation of gastric cancer in response to H. pylori infection: damage of epithelial cell DNA combined with downregulation of repair processes, mitochondrial DNA mutations, and appearance of tran-sient mutator phenotype. Park et al[129] showed thatshowed that after eradication of H. pylori the expression of proteins consisting DNA mismatch repair (MMR) system was increased. This proved that gastric inflammation due



to H. pylori infection impairs MMR[129]. Kim et al[130] co-cultured gastric cell lines with H. pylori and the proteins (MutS and MutL) of DNA MMR, and exam-ined quantitatively RNA levels. RNA of both proteins was reduced after exposure to H. pylori. Kidane et al[131] showed that damage of epithelial cell DNAshowed that damage of epithelial cell DNA due to oxidative stress, which increases during H. pylori infection is under control of base excision repair system and its effectiveness can be crucial for preventing genomic stability in response to H. pylori induced disorders. Toller et al[132] showed thatshowed that H. pylori strains having the BabA adhesin are very effective in inducing double-strand breaks.

Biomarkers for detection of gastric cancerEarly detection of adenocarcinoma is essential. The 5-year survival rate for patients suffering from advanced stomach cancer is lower than 30%. Currently, endoscopic surveillance is the most appli-cable method for cancer detection. However, endos-copy has disadvantages, such as the invasiveness of the test and its high cost. It has been shown that appropriate biomarkers provide information about the diagnosis, prognosis and recurrence of cancer, as well as the optimal therapy[133]. Nevertheless, gastric cancer biomarkers such as pepsinogen, gastrin or H. pylori serology combined with pepsinogen (PG), do not indicate very precisely the state of the patient[134]. Pepsinogen is produced in the stomach as pepsinogen I (PGI) and pepsinogen II (PGII). The blood levels of PGI and PGI/PGII change dur-ing atrophic gastritis due to destruction of gastric glands. A research study involving approximately 300000 participants was performed in order to verify this observation. The results showed that out of 600 patients with atrophic gastritis, one developed stomach cancer. A PGI/PGII ratio within the normal range was very accurate negative predictor of an unhealthy stomach[135,136]. Gastrin is also considered a biomarker for gastric atrophy, but the connection between the biomarker and the disease is com-plex[137,138]. Gastrin is produced in the antrum of the stomach. In the case of antrum atrophic gastritis, the biomarker indicates a low gastrin level, but in the case of corpus atrophic gastritis, the gastrin level is increased. Generally, low and high levels of gastrin predict atrophic gastritis and gastric cancer, respectively. However, gastrin as a biomarker does not provide information about the cancer stage. Furthermore, combined tests for the detection of H. pylori and the PGI/PGII value also help to detect gastric cancer[139]. Patients with a seronegative H. pylori result and PG within the norm have very low rates of cancer susceptibility. The risk rises in cases of H. pylori seropositivity and low PGI/PGII values, suggesting the presence of gastric atrophy. However, negative H. pylori testing accompanied by low PGI/PGII indicates the manifestation of autoim-

mune metaplastic atrophic gastritis. This condition is linked with advanced grades of metaplasia in the stomach[54,134].

A novel group of biomarkers is microRNAs (miR-NAs), which are nucleotides that modulate the expres-sion of genes. miRNAs influence cell proliferation and differentiation and may act as oncogenes. Cancer-related miRNAs have been found in the blood stream and can be detected noninvasively. Levels of miRNAs in healthy patients provide information about cancer susceptibility. However, in patients with gastric cancer, the levels of the biomarkers are associated with cancer stage, metastasis, recurrence and resistance to treatment. The inconsistent outcomes from several studies on miRNAs note the necessity for more tests on this biomarker[133,134].

Other cancers potentially related to H. pyloriH. pylori infection is linked to MALT lymphoma[109-111]. Nearly 98% of MALT lymphomas are H. pylori dependent because prolonged infection with the pathogen leads to proliferation of the lymphoid tissue. Eradication of H. pylori infection used as a cure for H. pylori-positive MALT lymphoma was found to correlate with the remission in 60%-80% of MALT-lymphoma cases[111,140]0]]. The presence of H. pylori in the host elevates the risk of developing other lymphomas, such as diffuse large B cell lymphoma and ocular adnexal lymphoma[3]. Contradictory results leave unclear the influence of the pathogen and of eradication therapy on carcinogenesis. Several studies have shown that H. pylori infection is correlated with laryngeal squamous cell carcinoma[140-142]. CagA-positive strains were found to cause a more severe condition and reduce the survival rate. However, not all cases confirm such an association[3]. Colorectal cancer development is also considered to be related to H. pylori infection[143-146]. High rates of mortality in specific regions from colorectal and stomach cancer, as well as high prevalence of the pathogen in critical colorectal adenomas point to H. pylori as a mutual risk factor. Some studies are in opposition to this theory because the pathomechanisms are not fully under-stood. An association between H. pylori infection and hepatocellular carcinoma has been suggested[147,148]. Esmat et al[149] have suggested that the presence ofhave suggested that the presence of CagA positive H. pylori strains in the liver may cause progression of hepatocellular carcinoma due to infec-tion with hepatitis C virus (HCV). The link between H. pylori infection and hepatic carcinoma has been confirmed by detection of genetic material of these bacteria in hepatic tissue[150]. The possibility of corela-tion between H. pylori infections and the development of pancreatic cancer has been suggested[151]. The role of gastric carriage of H. pylori CagA+ strains, in increasing a risk for gastric ulcer as well as gastric and pancreatic cancers was shown on the basis of seroprevalence of H. pylori by Stolzenberg-Solomon



et al[152]. Meta-analysis performed by Trikudanathan et al[153], suggested a reduced statistically significant association. In addition, other data support the hypothesis of a correlation between pancreatic cancer and H. pylori as well as the ABO genotype due to its role in gastric secretion and the secretory activity of the pancreas[154-156].

H. pylori DIVERSITY VS GASTRIC CANCER RISKCagA variationThe course of H. pylori infection depends on complex interactions between the microbial agent and the host genetic background, as well as host immune profile. H. pylori is a diverse microorganism. Specific features of an individual strain can determine the severity of inflammation and its consequences, including the promotion of malignancy. This diversity refers to the most important virulence factors, such as CagA, VacA toxin and OMPs.

CagA induces in vitro, the ‘hummingbird’ pheno-type of epithelial cells of the stomach with symptoms of cell elongation. These cellular changes are similar to epithelial-mesenchymal transition (EMT), which occurs during development of gastric cancer stem cells (CSC). H. pylori CagA promotes EMT phenotype, which was studied on the basis of both mesenchymal markers and CD 44 molecules associated with CSC[157]. The presence of CagA with phosphorylated Glu-Pro-Ile-Ala-Tyr, called the EPIYA motif, in host cells induces changes in the cytoskeleton, modifications of intercel-lular connections and deregulation of the expression of genes encoding transcription factors. EPIYA motifs in the C terminal region of CagA determine its interac-tion with numerous host proteins. Multimeric, non-phosphorylated CagA protein enhances the activity of phosphorylated CagA protein and contributes to the loss of cell polarity[11,28]. Within the EPIYA motif there is a phosphate acceptor tyrosine domain. This region is polymorphic since it contains different numbers of EPIYA motifs. Moreover, the diversity was also found in regions among EPIYA sequences. The length polymorphism at the 3’ end of the cagA gene results with increased phosphorylation of CagA protein, which enhance its biological activity and promotes more severe disease outcome[158]. Four EPIYA motifs have been described: -A, -B, -C, and -D. Their combination depends of geographic regions[159]. In general Western H. pylori strains possess EPIYA -A, -B, and -C whereas strains from East Asian region EPIYA -A, -B, and -D. The East Asian CagA-positive H. pylori strains are more closely associated with gastric cancer[160].

Vaziri et al[161] studied the influence of EPIYA motifs EPIYA motifsEPIYA motifs on the transcriptions of genes related to gastric cancer by using transfected gastric cancer AGS cell line with a eucaryotic vector carrying the cagA gene: ABC and ABCCC types. They found that the CagA oncoprotein. They found that the CagA oncoprotein

of ABCCC type can induce intestinal metaplasia, IL-8 production by epithelial cells, dysfunction of Crk adaptor proteins, and anti-apoptotic and carcinogenic effects more intensively than the CagA protein of the ABC type.

The association between the number of EPIYA-C regions and increased CagA tyrosine phosphorylation, protein tyrosine phosphatase (SHP)-2 binding activity, cytoskeletal alterations, IL-8 expression in gastric mucosa, development of the hummingbird cell phe-notype and severe disease frequency was found[162].

Western and East Asian CagA proteins differ in sequence among the EPIYA motifs. The FPLKRHD-KVDDLSKV sequence, which is present in Western type CagA in East-Asian type CagA is substituted by KIASAGKGVGGFSGA sequence. This amino acid sequence variation is supposed to be responsible for the higher frequency of gastric cancer in Japan as compared to the Western coutries[162]. Jones et al[159] verified that the East Asian EPIYA phenotype is closely related with disease development. Phosphorylated CagA regions are primarily EPIYA-C and -D sites, which are required for binding to SHP-2 and its activation[159].

Chattopadhyay et al[158] have suggested that in India, the infections related to different structures of CagA can be multiple. In this case the disease course is not determined by a particular type of CagA. They concluded that the risk of developing the disease is also associated with polymorphism of genes encod-ing other H. pylori proteins, as well as with the host genotype[158].

Research on a group of 436 Brazilian patients by Batista et al[163] showed that H. pylori strains in this region are the Western type and that there is a tight correlation between the number of EPIYA-C segments and increased risk of gastric carcinoma but not duo-denal ulcers[163] similarly as in Caucasian population from Italy and American patients in Texas[164,165].

Regardless of the C/D type, most CagA molecules include single A- and B- tyrosine phosphorylation motifs (TPMs) that do not undergo simultaneous tyrosine phosphorylation[166]. Phosphorylated A- or B-TPMs have host interaction partners distinct from C- or D-TPMs and from each other, suggesting unique signaling functions. Zhang et al[166] showed that in the Western population, also, the polymorphism of the EPIYA-B motifs influences the frequency of disease development, suggesting that a single nucleotide polymorphism in a major bacterial interactive com-pound could promote a disease outcome. In this In thisIn this study, the CagA B-TPM sequences showed the highest variability. The EPIYA motif was present in 72.6% of B-TPMs. However, other EPIYA-like motifs have been identified (EPIYT, ESIYT, ESIYA, GSIYD). The analysis carried out by Zhang et al[166] demonstrated that the association of EPIYT segments with gastric cancer is EPIYT segments with gastric cancer isEPIYT segments with gastric cancer is lower than the EPIYA motifs.

The correlation, which was found between EPIYA



motifs and the level of IL-8 as well as a strength of inflammatory response in gastic mucosa may depend on the geographical region[167]. Fajardo et al[162] andand Reyes-Leon et al[167] did not show correlation between the number of EPIYA-C motifs and IL-8 induction in the Columbian as well as Mexican population whereas Argent et al[168] obtained an opposite results for English population. Interestingly, Mexican and Columbian H. pylori strains share common predominant polymor-phisms (ABC and ABCC). Hatakeyama has suggested that CagA is involved in gastric carcinogenic processes through a hit-and-run mechanism, in which pro-oncogenic activities of CagA are successively taken over by a series of genetic and/or epigenetic altera-tions compiled in cancer-predisposing cells during long-lasting infection with cagA+ H. pylori[29].

VacA variantsVacA is a polymorphic toxin with pore forming activity and there are different allels of vacA gene within H. pylori strains. VacA is composed of four regions, which are further subdivided. The signal (s) region, which includes the N-terminus and a signal sequence is classified as s1 or s2[169]. The s region influences the formation of anion channel[170]. The mid (m) region, which affects host cell tropism, is classified as m1 or m2[169,170]. The intermediate (i) region is classified as i1, i2, or i3[169]. This region determines the vacu-olating and cancerogenic activity of VacA toxin[171]. The d region means the deletion of 81 bp between the i- and m-regions. Without deletion it is classified as d1 or d2 if a 69 to 89 base pair deletion is pres-ent[169,171]. VacA virulence depends on the combination of individual parts. The vacA s1/m1 alleles determine high cytotoxic activity of VacA. By comparison the s1/m2 and s2/m2 genotypes are not cytotoxic. The s1/m1 profile is strongly correlated with the outcome of duodenal ulcers, peptic ulcer disease, progression of preneoplastic lesions, and gastric cancer[169,170]. Ogiwara et al[172] showed that the risk of gastric cancer inshowed that the risk of gastric cancer in Western countries is related to the s1, m1, i1, and d1 polymorphisms, which are potentially linked with an increased neutrophil infiltration and gastric mucosal atrophy[171]. However, in other studies such a correla-tion was not found in East Asian countries[171,172].

It was found that i1 variants of the VacA protein have stronger vacuolating activity than i2 variants. Moreover, the i1 region is considered a better predictor of disease severity than the s1 and m1 variants in Western strains. The i region may contain A, B, and C polymorphic domains. The VacA toxicity depends on B and C part[170].

OMPsGenes encoding OMPs consist 4% of H. pylori genome. Many H. pylori OMPs belong to OMP family 1, which contains various H. pylori outer membrane proteins (Hop) and Hop-related proteins (Hor). H. pylori OMPs

are crucial for adaptation of the pathogen to the host. They play a role in bacterial movement and adhesion to gastric tissue[7]. Adhesins with known binding specificity include BabA (HopS), which binds Lewis (HopS), which binds Lewis(HopS), which binds Lewisb, a fucosylated blood-group antigen that is present in gastric tissue[31] and SabA (HopP), which is a sialic acid-binding adhesin associated with higher coloniza-tion density in humans[173]. The alpAB locus has been shown to encode the outer membrane adhesins AlpA and AlpB, which bind laminin[174]. The HorB protein is another adhesin, however, its ligand has not been identified[175].

The best-characterized OMP of H. pylori is BabA, which is encoded by the babA2 gene[176]. Research car-ried out by Torres et al[176] on a group of 130 H. pylori isolates from dyspeptic Cuban patients showed that the presence of a ‘triple positive’ genotype (vacAs1, cagA and babA2) (56.2% isolates) is correlated with the appearance of peptic ulcers, intestinal metaplasia and gastric cancer. Infection with these strains was found to be associated with a higher degree of inflam-mation and gastroduodenal lesions[176].

Research on 167 H. pylori-positive patients conducted by Zambon et al[177] allowed patients to be divided to four groups (A, B, C and D) on the basis of bacterial genotypes: cagA(-), s2 m2, babA2(-); cagA(+), s1 m1, babA2(+); cagA(+), s1 m2, babA2(+); cagA(+), s1 m2, babA2(-), respectively, that differ in their ability to induce gastrointestinal diseases. H. pylori strains of group B induced the worst inflammatory response including intestinal metapla-sia[177]. Moreover, a relationship between cagA and the s1 and m1 alleles of vacA and oipA was found. By comparison, H. pylori strains without cagA were usu-ally babA2(-) and oipA(-) and they held the s2 and m2 vacA alleles. This observation confirmed the role of the pathogenicity island as the main vehicle of virulence genes[177].

Another important Hop is HopH, encoded by the HP0638/hopH gene[178]. The hopH genotype has been foud related to H. pylori virulence markers including vacAs1, vacAm1, babA2, with the strongest association to cagA. The association of the hopH gene with gastric disorders could be due to promotion of increased bacterial adherence and colonization by the hopH. The expression of hopH has been found regulated by phase variation within a CT dinucleotide repeat motif[178].

Host genetic susceptibility and immune profileThe long lasting inflammation induced by H. pylori infection is followed by DNA damage, the impairement of repair processes and increased rate of mutations. These phenomena promote the development of H. pylori-related gastric carcinogenesis[128-132,179].

Pattern recognition receptorsPathogens possess many conservative PAMPs. These structures, which are present in various groups of



microorganisms, have not changed during evolution and do not occur in human organisms.These com-pounds are recognized by PRRs, which are deposited on immune cells as well as epithelial cells and vascular endothelium. TLRs and damage-associated molecular patterns (DAMPs) are representative PRRs[180,181].

Various groups of receptors are simultaneously engaged in recognition of H. pylori compounds and the development of gastric cancer. These are TLR2, TLR3, TLR4, TLR5, and TLR9; nucleotide-binding oligomerization domain (NOD)-like receptors (NLRs), such as NOD1, NOD2, and NLRP3 (NLR family pyrin domain containing 3); dendritic cell-specific intercel-lular grabbing non-integrin; retinoic acid-inducible gene (RIG)-I-like receptors (RIG-I); and melanoma differentiation associated protein 5. Polymorphisms in genes, which are involved in the signaling cascades via TLR, NLR, apoptosis-associated speck-like protein, and caspase recruitment domain containing protein 8 (CARD8) can increase the risk of H. pylori infection and gastric cancer[182,183]. This can happen because the dysfunction of genes, which are involved in cell signaling pathways via the above receptors may sig-nificantly modulate the host immune response during H. pylori infection[183].

TLR4TLRs recognize various H. pylori PAMPs, including flagellin (TLR5) and unmethylated CpG motifs (TLR9) as well as LPS (TLR4/TLR2)[183].

The expression of TLR2, TLR4 and TLR5 increases during gastric dysplasia and especially a strong corre-lation between TLR4 and gastric carcinoma has been suggested[184]. Additionally, Chochi et al[185] found thatfound that binding of H. pylori LPS to TLR4 resulted in increased growth of gastric adenocarcinoma. On this way also antitumor activity of human mononuclear cells was diminished.

In recent studies, much attention has been paid to the influence of TLR receptor polymorphisms on the development of diseases associated with H. pylori infection. Single nucleotide polymorphisms (SNPs) of the TLR4 receptor were connected with an increased risk of gastric carcinoma, including TLR4 rs4986790 (Asp299Gly)[186,187], TLR4 rs4986791 (Thr399Ile)[187], TLR4 rs10116253, TLR4 rs10983755, TLR4 rs11536889 (C3725G/C)[182], TLR4 rs1927911[183]. TLR4 Asp299Gly and Thr399Ile polymorphisms located in the encoding region have been considered the most important since they diminish the stability of the TLR4 extracel-lular domain[182,187].

Another study conducted by Bagheri et al[186] on a group of 195 patients with H. pylori infection and 241 H. pylori not-infected individuals confirmed that the increased frequency of TLR4 (Asp299Gly) G and DG alleles was related to chronic active gastritis. An A-G substitution at 896 bp was associated with a decreased response to LPS in vivo and in vitro and an

increased risk of inflammatory disease. The results obtained by Casta�o-Rodr�guezCasta�o-Rodr�guez et al[182] confirmedconfirmed that in the Western population the TLR4 Asp299Gly G allele as well as the TLR4 rs11536889 C allele and the CC genotype increased the risk of gastric cancer or other inflammation-related cancers. These results indicate that there is a relationship between the TLR4 rs11536889 polymorphism and increased incidence of cancer, which is consistent with the fact that the TLR4 rs11536889 polymorphism is located in the center of the 2818-bp TLR4 3’UTR and, therefore, may affect mRNA stability. However, other studies of polymor-phism investigated in Asian and Caucasian individuals have shown different risk associations with gastric cancer in an ethnic-specific manner[182].

TLR2In H. pylori infection, much attention is also focused on TLR2. It has been shown[188] that H. pylori LPS as TLR2 ligand induces the secretion of chemokines by gastric epithelial cells due to acting on tribbles 3 (TRIB3) protein, which is involved in the expression of the nuclear factor NF-κB. However, both TLR4 and TLR2 are engaged in the response of host immune cells against H. pylori, which effectiveness depends on the polymorphism of those receptors[183]. Meta-analysis of TLR2 -196 to -174 deletion and risk of gas-tric cancer conducted on 1364 gastric cancer patients and 2487 controls showed that there is an association between this polymorphism and risk of gastric cancer in the Japanese population. Polymorphism at this position decreases the induction of IL-8 secretion, thus impairing the response to H. pylori. Interestingly that correlation failed to be shown in the Chinese popula-tion, which may indicate an ethnic consideration in the incidence of stomach cancer[182].

CD14CD14 molecule and TLR4 both participate in the recog-nition of LPS[189]. During H. pylori infection monocytes and macrophages have been shown to release IL-12 in response to CD14 - dependent activation. This was correlated with the infiltration of gastric mucosa with T helper 1 lymphocytes and the maintenance of chronic inflammatory response[190].

Two SNPs identified in the promoter region of the CD14 gene: -260C/T (rs2569190 or CD14 -159) and -561C/T (rs5744455), have been suggested to increase the susceptibility to gastric cancer[182,191]. The CD14 -260 T allele had decreased affinity for the binding with DNA of transcription factors such as stimulatory proteins (SP) 1, SP2 and SP3 of which SP3 downregulates the activation of the cells by SP1 and SP2. Thus, the SP3 to SP1 and SP2 ratio might play an important role in the regulation of CD14 transcrip-tion[182,192,193]. Although an increased transcription activ-ity of this allele has been demonstrated in monocytes with low levels of SP3 a direct correlation between



CD14 polymorphism and gastric cancer incidence still needs to be investigated[190].

NODsThe NOD-like receptors detect PAMPs localized intracellularly as well as cellular DAMPs released due to elevated stress conditions. These receptors are involved in the development of innate immunity, regu-lation of inflammatory response and programmed cell death. Among NODs the binding specificity of NOD1 and NOD2 is different. NOD1 binds γ-D-glutamyl-meso-diaminopimelic acid whereas NOD2 muramyl dipeptide[194,195].

During H. pylori infection NOD1 is engaged in the induction of NF-κB and activator protein 1 (AP-1), which are involved in cytokine synthesis and cell acti-vation, thus triggering inflammatory response[190,196-198]. It has been shown that NOD1 regulates direct killing of H. pylori by antimicrobial peptides[199], enhances IFN-γ signaling in gastric epithelial cells during H. pylori infection, particularly with cag-PAI positive strains and exacerbates disease severity[198,200]. NOD2 induces pro-IL-1β and is necessary for the induction of NLRP containing protein 3 (scaffolidng proteins of inflam-masomes) in H. pylori-infected dendritic cells[201].

Polymorphism among NOD receptors also has an impact on the rate of stomach cancer incidence. Wang et al[202], carried out a test on a group of 296 patients with gastric cancer and 160 healthy subjects in the Chinese population, which showed that the NOD1 rs2907749 TT polymorphism reduced the likelihood of cancer of the stomach but NOD1 rs7789045 TT increased the incidence of stomach cancer (especially in the case of the NOD2 genotype rs7205423). An enhanced NOD1 expression was detected in H. pylori infected gastric mucosa. This might suggest that sig-naling via NOD1 determines gastric inflammation[202]. In general there is no association between NOD1/NOD2 mutations and gastritis as well as gastric ulcer. However, association between the R702W mutation in the NPD 2/CARD15 gene and gastric lymphoma has been found. The risk of gastric lymphoma is higher in those who carry allele T as compared to control individuals[200]. Companioni et al[203] have found a significant association between SNPs in CD14, NOD2 and TLR4. This study revealed that genetic variation in NOD2 associates with nocardia gastric cancer while variation in CD14 is associated with cardia gastric cancer.

INFLAMMATION DRIVEN MALIGNANCY RISKCytokinesDuring H. pylori infection the immune and gastric epithelial cells respond by the secretion of cytokines (pro- and anti-inflammatory). The level of cytokines might depend on polymorphisms of the genes encod-

ing specific cytokines including tumor necrosis factor (TNF)-α, IL-1, IL-8 and Il-10[204]. Genetic polymor-phisms have been considered as factors increasing cytokine levels and susceptibility for cancer develop-ment due to hypochloridria[205].

IL-1IL-1 (IL-1α and IL-1β), is a pro-inflammatory cytokine and IL-1 receptor antagonist (IL-1Ra) possess a natural anti-inflammatory activity. The initiation or the maintenance of inflammation depend on the bal-ance between IL-1β and IL-1Ra[204]. IL-1β and IL-1RN gene polymorphisms increase risk of hypochloridria and gastric carcinoma. This is because the elevated levels of IL-1 initiate spontaneous inflammation, which then can be followed by dysplasia and gastric carcinoma through an activation of the IL-1/NF-κB pathway[206-208]. It has been shown that IL-1β signi-ficantly amplifies inflammatory response during H. pylori infections[204,205]. Ramis et al[204]], investigated in the IL-1B gene three SNPs (C-T transition at -31 position; C-T transitions at -511 and +3954 positions), associated with an enhanced secretion of IL-1β. In H. pylori infected patients there was a correlation between IL-1β level and the T/T genotype (-511 position) as well as the C/C genotype (-31 position). In such patients an increased risk of gastritis but not peptic ulcer and gastric carcinoma has been found. This research group also proved that patients with the T/T genotype of IL-1B (-511 position) were more frequently infected with H. pylori cagA(+) strains. There was no correlation between IL-1B gene polymorphisms at position +3954 and increased prevalence of H. pylori infection as well as H. pylori-derived diseases[204].

However, in the Costa Rican population two proin-flammatory genotypes IL-1B+3954 T/C and IL-1RN*2/L were foud related to gastric cancer cases[209]. Caleman Neto et al[210], have suggested that the IL-1B -31T/T polymorphism acts as a protective factor against H. pylori infection in the Brazilian population.

Contrary to previous studies, Al-Moundhri et al[211], has proven that the widely reported association bet-ween IL-1B -31/-511 polymorphism and gastric cancer was not established in the Omani Arab population, supporting the ethnic differences in the effect of IL-1B polymorphism on gastric cancer development.

IL-1RNIl-1RN as an antagonist of the IL-1 receptor modu-lates its activity. The most intensively studied IL-1RN polymorphism connected to gastric cancer outcome is a 86-bp variable number of tandem repeats poly-morphism in the IL-1RN second intron (IL-1RN*2)[208]. The study carried out on the Brazilian Amazon popula-tion by Melo Barbosa et al[205], showed that among patients with gastric ulcer and adenocarcinoma there was a higher frequency of allele 2 carriers (IL-1RN*2).



The IL-1Ra protein (encoded by the IL-1RN gene) competes with the IL-1 receptor to inhibit the action induced by IL-1β. The presence of the IL-1RN*2 vari-ant is connected with the increased levels of IL-1β in the gastric mucosa and to hypochlorhidria in compari-son to IL-1RN1/1 variant[205]. Research performed on a Research performed on aResearch performed on a group of 118 gastric cancer patients and 245 healthy controls also supported the correlation between the presence of the IL-RN*2 allele and the increase in the gastric cancer ratio in the Arab population[211].

Tumor necrosis factor alphaTNF-α is a cell signaling protein involved in systemic inflammation and acute phase reaction. This cytokine is produced by activated macrophages, CD4+ lympho- macrophages, CD4+ lympho-macrophages, CD4+ lympho-cytes, NK cells, neutrophils, mast cells, eosinophils, mast cells, eosinophils,mast cells, eosinophils, eosinophils,eosinophils, and neurons. It takes part in the regulation of immune cell activity, fever induction, apoptotic cell death, cachexia, inflammation, inhibition of tumorigenesis and viral replication. It is also involved in the cytokine response during sepsis[212,213]. The elevated secre-tion of TNF-α is observed in the gastric mucosa of H. pylori infected patients where this cytokine induces cell apoptosis[214]. The activity of TNF-α is regulated by soluble TNF receptors (sTNF-Rs), which potentially protect gastric epithelial cells colonized by H. pylori from apoptosis[214].

TNF-α activity and concentration can be influenced by SNPs (G to A transitions at -308A and -238 posi--308A and -238 posi-308A and -238 posi--238 posi-238 posi-tions) in the promoter region of TNF-α gene[215]. In the Korean population the transition at -308 position was related with a CagA(+) H. pylori infections and its severe consequences. The biallelic polymorphismhe biallelic polymorphism at this position is associated with the development of gastric carcinoma in the Caucasian population[205].

The binding of AP-2 to -308 region was found by-308 region was found by308 region was found by Yea et al alal[215] to be altered by the −308A allele. Due to this -308A polymorphism might lead to an increase in-308A polymorphism might lead to an increase in308A polymorphism might lead to an increase in TNF-α gene expression[215].

The latest results of meta-analysis obtained by Sun et al[216] demonstrate that TNF-α -308G/A and -1031 T/C polymorphisms may be protective factors against H. pylori infection, whereas -863C/A substitution may be a risk factor, especially in Asian populations. The authors also showed that there was no significant association between -857C/T polymorphism and H. pylori infection while -863C/A significantly increased the risk of infection. Moreover, the -1031T/C polymor-phism decreased this risk for the Asian subgroup and hospitalized patients[216].

IL-10IL-10 is a pleiotropic cytokine, which has the ability to suppress or stimulate anti-cancer properties of immune cells. This cytokine downregulates the pro-duction of pro-inflammatory cytokines by inhibition of Th 1 lymphocytes and stimulation of B, as well as Th 2, lymphocytes and thus downregulates the inflam-

matory response[212,213]. Since 2003 researchers have consistently reported associations between IL-10- 592 A/C SNP and susceptibility to gastric cancer but with mixed or conflicting results[217]. A meta- analysis performed by Ni et al[218] indicated that inindicated that in Asian populations the carriers of IL-10 -1082 GG-plus-GA genotypes are more susceptible to all types of gastric cancer.

Kim et al[219] investigated three IL-10 promoter polymorphisms: -1082A/G, -819T/C, and -592 A/C probably related to elevated levels of IL-10. These polymorphisms were associated with an increased risk of intestinal-type noncardiac gastric cancer but only in H. pylori infected smokers[219].

Con et al[209] showed that theshowed that the IL-10 -592 A/A or -592 C/A polymorphisms were associated with an increased risk of gastric cancer in the Costa Rican population. In the above study the IL-1β +3954 T/C, IL-1RN*2/L and IL-10: -592 C/A polymorphisms, in the patients infected with H. pylori vacA s1b/m1 strains have been found to predispose them to gastric cancer. It means that synergistic effect of bacterial and host genotypes may influence the course and the consequences of H. pylori infection[209].

IL-8During early phase of H. pylori infection a chemotactic IL-8 induces infiltration of granulocytes to the site of infection and induction of phagocytosis once they have arrived[204]. Activation of phagocytes in the inflam-matory milieu may result in gastric barrier damage due to releasing of proteolytic enzymes and reactive oxygen radicals[220].

As in the case of other cytokine polymorphisms, IL-8 differentiation is also the subject of research. Caleman Neto et al[210] suggested that in Easternsuggested that in Eastern populations the elevated production of IL-8 and the intensity of the inflammatory response depends on the presence of the A allele in the promoter region of the IL-8 gene (-251 position).

Ohyauchi et al[220] investigated a correlation bet-ween IL-8 polymorphism and gastroduodenal disease outcome during H. pylori infection in the Japanese population. Thy showed that in Thy showed that inThy showed that in H. pylori infected patients the presence of IL-8 -251A allele was linked with the gastric ulcer, gastric atrophy and then cancer. This study confirmed that, in comparison to the IL-8 -251T variant, IL-8 -251A transcription is activated in more active gastritis with strong neutrophil infiltration. These results have been confirmed by the study of Caleman Neto et al[210], performed with 60 patients, which showed that the IL-8 -251TT genotype could protect whereas the IL-8 -251TA genotype could promote the H. pylori infection.

Cyclooxygenase-2Cyclooxygenase-2 (COX-2) catalyzes the conver-sion of arachidonic acid to prostaglandins and its



production increases in response to growth factors, cytokines and mitogens. COX-2 is often undetectable in normal tissues, whereas in tumor tissue specimens its expression is higher[221,222]. Specifically, increased COX-2 expression is linked to the progression of gastric cancer and precancerous tissues by activating angiogenesis, inhibiting apoptosis, and accelerating invasion and metastasis[221]. In addition to cytokine polymorphisms, genetic differentiation of cyclooxy-genase also plays an important role in the develop-ment of H. pylori-associated gastric diseases[222]. Concerning the polymorphisms of promoter region of COX-2 (1195G/A and -765G/C), Li, LiLi et al[222] showedshowed that the increased risk of gastric cancer appears in the carriers of the COX-2-1195AA but not of the COX-2-765G/C genotype.

Meta-analysis carried out by Zhao et al[221] showed that the -765G/C polymorphism (rs20417) in the promoter region of the COX-2 gene could be a risk factor for gastric cancer in Asians and Indians. This SNP affects the transcription and functional activity of COX-2. The COX-2-765G/C polymorphism was significantly associated with an increased risk of gastric cancer, regardless of H. pylori infection.

Polymorphisms involved in deregulation of T cell responseGastric MALT lymphoma depends on the activation of specific T lymphocytes, which undergo regulation through different mechanisms. It depends on cytotoxic T-lymphocyte antigen (CTLA) 4 as well as CD28 and inducible costimulator (ICOS) genes[223-225]. Genotyping of CTLA 4 gene (49 A/G, -318 C/T, CT60 A/G), CD28 gene (IVS3+ 17T/C), and ICOS gene (c.602 A/C and c.1624C/T) has been performed by Cheng et al[226] in the gastric MALT lymphoma patients with or without H. pylori infection and healthy individuals. The CTLA 4 -318 C/T genotype was associated with a lower whereas the CTLA 4 49 G/G genotype with a higher risk of MALT lymphoma. In H. pylori-positive patients, the susceptibility to MALT lymphoma was four times higher in the case of the carriage of -318C -49G haplotype.

CONCLUSIONH. pylori has evolved during long cohabitation withhas evolved during long cohabitation with humans. The colonization of the host stomach at a young age, persistence in this specific niche for its lifetime, subversion of the human immune system by hypoinflammatory LPS and molecular mimicry, and induction of gastritis and cancer development make H. pylori a complex pathogen. The clinical aspects of H. pylori depend on several conditions, such as the location of infection, the host susceptibility, the bacte-rial strain and environmental factors. The virulence strategies of bacterial CagA-positive strains, as well as low socioeconomic status of the patient, influence

the outcome of the infection. The highest prevalence rates of infection are reported in Asia and Africa. For years H. pylori infection might remain asymptomatic in spite of the developing condition. Medication for chronic gastritis or peptic ulcers involves antibiotic therapy. Sequential therapy is the most efficient treat-ment to cure the infection. To prevent the occurrence of antibiotic resistance, only cases with clinical symp-toms or asymptomatic patients in a risk group ought to be treated. Adequate results for H. pylori detection are provided by the non-invasive urea breath test and invasive nested PCR. Eradication of the infection typically leads to improved patient health, but it may allow the development of gastroesophageal disease and asthma. The intensity of the infection reflects the ability of H. pylori to induce extragastric diseases. Chronic atrophic gastritis is the precursor condition for ulceration and gastric malignancy. Classified as a group I carcinogen and causing nearly 670 thousand new cancer cases every year, H. pylori has become a threat to our lives. Specific biomarkers are crucial for early diagnosis of gastric cancer. Although H. pylori is one of the most studied pathogens of the upper gastrointestinal tract, many of its mechanisms of action are still not well understood.

REFERENCES1 Lina TT, Alzahrani S, Gonzalez J, Pinchuk IV, Bes�ick EJ, Reyes

VE. Immune evasion strategies used by Helicobacter pylori. World J Gastroenterol 2014;2014; 20: 12753-12766 [PMID: 25278676 DOI: 10.3748/�jg.v20.i36.12753]

2 Marshall BJ, W�arren JR. Unidentified curved bacilli in the stom-ach of patients �ith gastritis and peptic ulceration. Lancet 1984; 1: 1311-1315 [PMID: 6145023]

3 Testerman TL, Morris J. Beyond the stomach: an updated vie� of Helicobacter pylori pathogenesis, diagnosis, and treatment. World J Gastroenterol 2014;2014; 20: 12781-12808 [PMID: 25278678 DOI: 10.3748/�jg.v20.i36.12781]

4 Hagymási K, Tulassay Z. Helicobacter pylori infection: ne� pathogenetic and clinical aspects. World J Gastroenterol 2014; 20: 6386-6399 [PMID: 24914360 DOI: 10.3748/�jg.v20.i21.6386]

5 Shim JH, Yoon JH, Choi SS, Ashktorab H, Smoot DT, Song KY, Nam SW�, Lee JY, Park CH, Park W�S. The effect of Helicobacter pylori CagA on the HER-2 copy number and expression in gastric cancer. Gene 2014; 546: 288-296 [PMID: 24879917 DOI: 10.1016/j.gene.2014.05.064]

6 Testerman TL , McGee DJ, Mobley H. Adherence and Adherence andAdherence and Colonization. In: Helicobacter pylori: Physiology and Genetics, Mobley H, Mendz GL, Hazell SL (red.). ASM press, W�ashington (red.). ASM press, W�ashington(red.). ASM press, W�ashington (DC), 2001; page 381-419 [DOI: 10.1128/9781555818005.ch34]; page 381-419 [DOI: 10.1128/9781555818005.ch34]page 381-419 [DOI: 10.1128/9781555818005.ch34]

7 Oleastro M, Ménard A. The Role of Helicobacter pylori Outer Membrane Proteins in Adherence and Pathogenesis. Biology (Basel) 2013; 2: 1110-1134 [PMID: 24833057 DOI: 10.3390/biology2031110]

8 Mahdavi J, Sondén B, Hurtig M, Olfat FO, Forsberg L, Roche N, Angstrom J, Larsson T, Teneberg S, Karlsson KA, Altraja S, W�adström T, Kersulyte D, Berg DE, Dubois A, Petersson C, Magnusson KE, Norberg T, Lindh F, Lundskog BB, Arnqvist A, Hammarström L, Borén T. Helicobacter pylori SabA adhesin in persistent infection and chronic inflammation. Science 2002; 297: 573-578 [PMID: 12142529 DOI: 10.1126/science.1069076]

9 Aspholm M, Olfat FO, Nordén J, Sondén B, Lundberg C, Sjöström R, Altraja S, Odenbreit S, Haas R, W�adström T, Engstrand L,



Semino-Mora C, Liu H, Dubois A, Teneberg S, Arnqvist A, Borén T. SabA is the H. pylori hemagglutinin and is polymorphic in binding to sialylated glycans. PLoS Pathog 2006; 2: e110 [PMID: 17121461 DOI: 10.1371/journal.ppat.0020110]

10 Ishijima N, Suzuki M, Ashida H, Ichika�a Y, Kanegae Y, Saito I, Borén T, Haas R, Sasaka�a C, Mimuro H. BabA-mediated adher-ence is a potentiator of the Helicobacter pylori type IV secretion system activity. J Biol Chem 2011; 286: 25256-25264 [PMID: 21596743 DOI: 10.1074/jbc.M111.233601]

11 Alzahrani S, Lina TT, Gonzalez J, Pinchuk IV, Bes�ick EJ, Reyes VE. Effect of Helicobacter pylori on gastric epithelial cells. World J Gastroenterol 2014; 20: 12767-12780 [PMID: 25278677 DOI: 10.3748/�jg.v20.i36.12767]

12 McGee DJ, George AE, Trainor EA, Horton KE, Hildebrandt E, Testerman TL. Cholesterol enhances Helicobacter pylori resistance to antibiotics and LL-37. Antimicrob Agents Chemother 2011; 55: 2897-2904 [PMID: 21464244 DOI: 10.1128/AAC.00016-11]

13 Muotiala A, Helander IM, Pyhälä L, Kosunen TU, Moran AP. Lo� biological activity of Helicobacter pylori lipopolysaccharide. Infect Immun 1992;1992; 60: 1714-1716 [PMID: 1548097]

14 Moran AP, Aspinall GO. Unique structural and biological features of Helicobacter pylori lipopolysaccharides. Prog Clin Biol Res 1998; 397: 37-49 [PMID: 9575546]

15 Paziak-Domańska B�� Ch�i�l� M�� J��sińs�� A�� Ru��i�� Potential role of CagA in the inhibition of T cell reactivity in Helicobacter pylori infections. Cell Immunol 2000; 202: 136-139 [PMID: 10896773 DOI: 10.1006/cimm.2000.1654]

16 Grebowska A, Moran AP, Bielanski W�, Matusiak A, Rechcinski T, Rudnicka K, Barano�ska A, Rudnicka W�, Chmiela M. Helicobacter pylori lipopolysaccharide activity in human peripheral blood mononuclear leukocyte cultures. cultures.cultures. J Physiol Pharmacol 2010; 61: 437-442 [PMID: 20814071]

17 Rudnicka K, Miszczyk E, Matusiak A, W�alencka M, Moran AP, Rudnicka W�, Chmiela M. Helicobacter pylori-driven modulation of NK cell expansion, intracellular cytokine expression and cytotoxic activity. Innate Immun 2015; 21: 127-139 [PMID: 24448078 DOI: 10.1177/1753425913518225]

18 Mnich E, Gaje�ski A, Rudnicka K, Gonciarz W�, Sta�erski P, Hinc K, Obucho�ski M, Chmiela M. Immunoregulation of antigen pre-senting and secretory functions of monocytic cells by Helicobacter pylori antigens in relation to impairment of lymphocyte expansion. Acta Biochim Pol 2015; 62: 641-650 [PMID: 26523406 DOI: 10.18388/abp.2015_1045]

19 Appelmelk BJ, Simoons-Smit I, Negrini R, Moran AP, Aspinall GO, Forte JG, De Vries T, Quan H, Verboom T, Maaskant JJ, Ghiara P, Kuipers EJ, Bloemena E, Tadema TM, To�nsend RR, Tyagarajan K, Crothers JM, Monteiro MA, Savio A, De Graaff J. Potential role of molecular mimicry bet�een Helicobacter pylori lipopolysaccharide and host Le�is blood group antigens in autoim-munity. Infect Immun 1996; 64: 2031-2040 [PMID: 8675304]

20 Heneghan MA, McCarthy CF, Moran AP. Relationship of blood group determinants on Helicobacter pylori lipopolysac-charide �ith host le�is phenotype and inflammatory response. Infect Immun 2000; 68: 937-941 [PMID: 10639467 DOI: 10.1128/IAI.68.2.937-941.2000]

21 Chmiela M, Miszczyk E, Rudnicka K. Structural modifications of Helicobacter pylori lipopolysaccharide: an idea for ho� to live in peace. World J Gastroenterol 2014; 20: 9882-9897 [PMID: 25110419 DOI: 10.3748/�jg.v20.i29.9882]

22 Olofsson A, Nygård Skalman L, Obi I, Lundmark R, Arnqvist A. Uptake of Helicobacter pylori vesicles is facilitated by clathrin-dependent and clathrin-independent endocytic path�ays. MBio 2014; 5: e00979-e00914 [PMID: 24846379 DOI: 10.1128/mBio. 00979-14]

23 Parker H, Chitcholtan K, Hampton MB, Keenan JI. Uptake of Helicobacter pylori outer membrane vesicles by gastric epithelial cells. Infect Immun 2010; 78: 5054-5061 [PMID: 20876296 DOI: 5054-5061 [PMID: 20876296 DOI:5054-5061 [PMID: 20876296 DOI: 10.1128/IAI.00299-10]

24 Censini S, Lange C, Xiang Z, Crabtree JE, Ghiara P, Borodovsky M, Rappuoli R, Covacci A. cag, a pathogenicity island of

Helicobacter pylori, encodes type I-specific and disease-associated virulence factors. Proc Natl Acad Sci USA 1996; 93: 14648-14653 [PMID: 8962108 DOI: 10.1073/pnas.93.25.14648]

25 Backert S, Clyne M, Tegtmeyer N. Molecular mechanisms of gas-tric epithelial cell adhesion and injection of CagA by Helicobacter pylori. Cell Commun Signal SignalSignal 2011; 9: 28 [PMID: 22044679 DOI: 10.1186/1478-811X-9-28]

26 Peek RM, Blaser MJ. Helicobacter pylori and gastrointestinal tract adenocarcinomas. Nat Rev Cancer 2002; 2: 28-37 [PMID: 11902583 DOI: 10.1038/nrc703]

27 Yamaoka Y. Mechanisms of disease: Helicobacter pylori virulence factors. Nat Rev Gastroenterol Hepatol 2010; 7: 629-641 [PMID: 20938460 DOI: 10.1038/nrgastro.2010.154]

28 Aziz F, Chen X, Yang X, Yan Q. Prevalence and correlation �ith clinical diseases of Helicobacter pylori cagA and vacA genotype among gastric patients from Northeast China. Biomed Res Int 2014; 2014: 142980 [PMID: 24949419 DOI: 10.1155/2014/142980]

29 Hatakeyama M. Helicobacter pylori CagA and gastric cancer: a paradigm for hit-and-run carcinogenesis. Cell Host Microbe 2014; 15: 306-316 [PMID: 24629337 DOI: 10.1016/j.chom.2014.02.008]

30 Borén T, Falk P, Roth KA, Larson G, Normark S. Attachment of Helicobacter pylori to human gastric epithelium mediated by blood group antigens. Science 1993; 262: 1892-1895 [PMID: 8018146 DOI: 10.1126/science.8018146]

31 Evans DJ, Evans DG. Helicobacter pylori adhesins: revie� and perspectives. Helicobacter 2000; 5: 183-195 [PMID: 11179982 DOI: 10.1046/j.1523-5378.2000.00029.x]

32 Blaser MJ. Helicobacter pylori: microbiology of a ‘slo�’ bacterial infection. Trends Microbiol MicrobiolMicrobiol 1993; 1: 255-260 [PMID: 8162405 DOI: 10.1016/0966-842X(93)90047-U]

33 Wroblewski LE, Shen L, Ogden S, Romero-Gallo J, Lapierre LA, Israel DA, Turner JR, Peek RM. Helicobacter pylori dysregulation of gastric epithelial tight junctions by urease-mediated myosin II activation. Gastroenterology 2009;2009; 136: 236-246 [PMID: 236-246 [PMID:236-246 [PMID: 18996125 DOI: 10.1053/j.gastro.2008.10.011]

34 Posselt G, Backert S, W�essler S. The functional interplay of Helicobacter pylori factors �ith gastric epithelial cells induces a multi-step process in pathogenesis. Cell Commun Signal 2013; 11: 77 [PMID: 24099599 DOI: 10.1186/1478-811X-11-77]

35 Cadamuro AC, Rossi AF, Matos Biselli-Périco J, Fucuta Pereira P, Do Vale EP, Acayaba R, Leite KR, Goloni-Bertollo EM, Silva AE. Effect of Helicobacter pylori eradication on TLR2 and TLR4 expression in patients �ith gastric lesions. Mediators Inflamm 2015; 2015: 481972 [PMID: 25873761 DOI: 10.1155/2015/481972]

36 Bäckhed F, Rokbi B, Torstensson E, Zhao Y, Nilsson C, Seguin D, Normark S, Buchan AM, Richter-Dahlfors A. Gastric mucosal recognition of Helicobacter pylori is independent of Toll-like pylori is independent of Toll-likepylori is independent of Toll-like receptor 4. J Infect Dis 2003; 187: 829-836 [PMID: 12599057 DOI: 10.1086/367896]

37 Allen LA, Schlesinger LS, Kang B. Virulent strains of Helicobacter pylori demonstrate delayed phagocytosis and stimulate homotypic phagosome fusion in macrophages. J Exp Med 2000; 191: 115-128 [PMID: 10620610 DOI: 10.1084/jem.191.1.115]

38 Kim JM, Kim JS, Yoo DY, Ko SH, Kim N, Kim H, Kim YJ. Stimulation of dendritic cells �ith Helicobacter pylori vacuolating cytotoxin negatively regulates their maturation via the restoration of E2F1. Clin Exp Immunol 2011;2011; 166: 34-45 [PMID: 21910723 34-45 [PMID: 2191072334-45 [PMID: 21910723 DOI: 10.1111/j.1365-2249.2011.04447.x]

39 Grebowska A, Moran AP, Matusiak A, Bak-Romaniszyn L, C��i��i�� E�� R��h�ińs��i T�� l�� M�� ł��-M�ł�� I�� Rudnicka W�, Chmiela M. Anti-phagocytic activity of Helicobacter pylori lipopolysaccharide (LPS)--possible modulation of the innate immune response to these bacteria. Pol J Microbiol 2008;2008; 57: 185-192 [PMID: 19004238]

40 Richter C, Mukherjee O, Ermert D, Singh B, Su YC, Agar�al V, Blom AM, Riesbeck K. Moonlighting of Helicobacter pylori catalase protects against complement-mediated killing by utilising the host molecule vitronectin. Sci Rep 2016;2016; 6: 24391 [PMID: 27087644 DOI: 10.1038/srep24391]



41 Bergman MP, Engering A, Smits HH, van Vliet SJ, van Bodegraven AA, W�irth HP, Kapsenberg ML, Vandenbroucke-Grauls CM, van Kooyk Y, Appelmelk BJ. Helicobacter pylori modulates the T helper cell 1/T helper cell 2 balance through phase-variable interaction bet�een lipopolysaccharide and DC-SIGN. J Exp Med 2004; 200: 979-990 [PMID: 15492123 DOI: 10.1084/jem.20041061]

42 Miszczyk E, Rudnicka K, Moran AP, Fol M, Ko�ale�icz-Kulb�� M�� D�us��yńs�� M�� M��usi�� A�� l�� M�� Ru��i�� W�, Chmiela M. Interaction of Helicobacter pylori �ith C-type lectin dendritic cell-specific ICAM grabbing nonintegrin. J Biomed Biotechnol 2012; 2012: 206463 [PMID: 22550396 DOI: 10.1155/2012/206463]

43 Miszczyk E, W�alencka M, Rudnicka K, Matusiak A, Rudnicka W�, Chmiela M. Antigen-specific lymphocyte proliferation as a marker of immune response in guinea pigs �ith sustained Helicobacter pylori infection. Acta Biochim Pol PolPol 2014; 61: 295-303 [PMID: 24918491]

44 Enarsson K, Lundgren A, Kindlund B, Hermansson M, Roncador G, Banham AH, Lundin BS, Quiding-Järbrink M. Function and recruitment of mucosal regulatory T cells in human chronic Helicobacter pylori infection and gastric adenocarcinoma. Clin Immunol 2006; 121: 358-368 [PMID: 16934529 DOI: 10.1016/j.clim.2006.07.002]

45 Das S, Suarez G, Bes�ick EJ, Sierra JC, Graham DY, Reyes VE. Expression of B7-H1 on gastric epithelial cells: its potential role in regulating T cells during Helicobacter pylori infection. J Immunol 2006; 176: 3000-3009 [PMID: 16493058]

46 Kandulski A, W�ex T, Kuester D, Peitz U, Gebert I, Roessner A, Malfertheiner P. Naturally occurring regulatory T cells (CD4+, CD25high, FOXP3+) in the antrum and cardia are associated �ith higher H. pylori colonization and increased gene expression of TGF-beta1. Helicobacter 2008; 13: 295-303 [PMID: 18665940 DOI: 10.1111/j.1523-5378.2008.00612.x]

47 O’Keeffe J, Moran AP. Conventional, regulatory, and uncon-ventional T cells in the immunologic response to Helicobacter pylori. Helicobacter 2008; 13: 1-19 [PMID: 18205661 DOI: 10.1111/j.1523-5378.2008.00559.x]

48 Wroblewski LE, Peek RM, W�ilson KT. Helicobacter pylori and gastric cancer: factors that modulate disease risk. Clin Microbiol Rev 2010; 23: 713-739 [PMID: 20930071 DOI: 10.1128/CMR. 00011-10]

49 Kao JY, Zhang M, Miller MJ, Mills JC, W�ang B, Liu M, Eaton KA, Zou W�, Berndt BE, Cole TS, Takeuchi T, O�yang SY, Luther J. Helicobacter pylori immune escape is mediated by dendritic cell-induced Treg ske�ing and Th17 suppression in mice. Gastroenterology 2010; 138: 1046-1054 [PMID: 19931266 DOI: 10.1053/j.gastro.2009.11.043]

50 Kabir S. The role of interleukin-17 in the Helicobacter pylori induced infection and immunity. Helicobacter 2011; 16: 1-8 [PMID: 21241406 DOI: 10.1111/j.1523-5378.2010.00812.x]

51 Bhuiyan TR, Islam MM, Uddin T, Cho�dhury MI, Janzon A, Adamsson J, Lundin SB, Qadri F, Lundgren A. Th1 and Th17 responses to Helicobacter pylori in Bangladeshi infants, children and adults. PLoS One 2014; 9: e93943 [PMID: 24714675 DOI: 10.1371/journal.pone.0093943]

52 Anderl F, Gerhard M. Helicobacter pylori vaccination: is there a path to protection? World J Gastroenterol 2014; 20: 11939-11949 [PMID: 25232229 DOI: 10.3748/�jg.v20.i34.11939]

53 Akhiani AA , Schön K, Franzén LE, Pappo J, Lycke N. Helicobacter pylori-specific antibodies impair the development of gastritis, facilitate bacterial colonization, and counteract resistance against infection. J Immunol 2004;2004; 172: 5024-5033 [PMID: 15067084]

54 Eusebi LH, Zagari RM, Bazzoli F. Epidemiology of Helicobacter pylori infection. Helicobacter 2014; 19 Suppl 1: 1-5 [PMID: 25167938 DOI: 10.1111/hel.12165]

55 Mitchell HM. Epidemiology of InfectionIn. In: Mobley HL,Epidemiology of InfectionIn. In: Mobley HL,. In: Mobley HL,In: Mobley HL, Mendz GL, Hazell SL, editors. Helicobacter pylori: Physiology and Genetics. W�ashington (DC): ASM Press 2001; Chapter 2 [PMID: [PMID:[PMID:

21290723 DOI: 10.1128/9781555818005.ch2]56 Konno M, Yokota S, Suga T, Takahashi M, Sato K, Fujii N.

Predominance of mother-to-child transmission of Helicobacter pylori infection detected by random amplified polymorphic DNA fingerprinting analysis in Japanese families. Pediatr Infect Dis J 2008; 27: 999-1003 [PMID: 18845980 DOI: 10.1097/INF.0b013e31817d756e]

57 Malfertheiner P. The intriguing relationship of Helicobacter pylori infection and acid secretion in peptic ulcer disease and gastric cancer. Dig Dis 2011; 29: 459-464 [PMID: 22095010 DOI: 10.1159/00033221]

58 Yamaoka Y. Pathogenesis of Helicobacter pylori-Related Gastroduodenal Diseases from Molecular Epidemiological Studies. Gastroenterol Res Pract 2012;2012; 2012: 371503 [PMID: 22829807 DOI: 10.1155/2012/371503]

59 Walker MM, Talley NJ. Revie� article: bacteria and pathogenesis of disease in the upper gastrointestinal tract--beyond the era of Helicobacter pylori. Aliment Pharmacol Ther 2014; 39: 767-779 [PMID: 24612362 DOI: 10.1111/apt.12666]

60 Tiwari SK, G M, Khan AA, Habeeb A, Habibullah CM. Chronic Idiopathic Thrombocytopenia Purpura and Helicobacter pylori Eradication: A case study. Gastroenterology Res 2009; 2: 57-59 [PMID: 27956954 DOI: 10.4021/gr2009.02.1271]

61 Desai HG, Gupte PA. Helicobacter pylori link to pernicious anaemia. J Assoc Physicians India 2007; 55: 857-859 [PMID: 18405134]

62 Muhsen K, Cohen D. Helicobacter pylori infection and iron stores: a systematic revie� and meta-analysis. Helicobacter 2008; 13: 323-340 [PMID: 19250507 DOI: 10.1111/j.1523-5378.2008.00617.x]

63 Zhang ZF, Yang N, Zhao G, Zhu L, Zhu Y, W�ang LX. Effect of Helicobacter pylori eradication on iron deficiency. Chin Med J (Engl) 2010; 123: 1924-1930 [PMID: 20819579]

64 Ozkasap S, Yarali N, Isik P, Bay A, Kara A, Tunc B. The role of prohepcidin in anemia due to Helicobacter pylori infection. Pediatr Hematol Oncol 2013; 30: 425-431 [PMID: 23560993 DOI: 10.3109/08880018.2013.783144]

65 Papagiannakis P, Michalopoulos C, Papalexi F, Dalampoura D, Diamantidis MD. The role of Helicobacter pylori infection in hematological disorders. Eur J Intern Med 2013; 24: 685-690 [PMID: 23523153 DOI: 10.1016/j.ejim2013.02.011]

66 Kobayashi Y, Hatta Y, Uchino Y. Successful treatment of second-ary Helicobacter pylori eradication for chronic immune thrombo-cytopenic purpura. Platelets 2014; 25: 645 [PMID: 24205803 DOI: 10.3109/09537104.2013.857395]

67 Yadav MK , Rishi JP, Nija�an S. Chronic urticaria and Helicobacter pylori. Indian J Med Sci 2008; 62: 157-162 [PMID: 18445982 DOI: 10.4103/0019-5359.40579]

68 Ben Mahmoud L, Ghozzi H, Hakim A, Sahnoun Z, Zeghal K. Helicobacter pylori associated �ith chronic urticaria. J Infect Dev Ctries 2011; 5: 596-598 [PMID: 21841304]

69 Hernando-Harder AC, Booken N, Goerdt S, Singer MV, Harder H. Helicobacter pylori infection and dermatologic diseases. Eur J Dermatol 2009;; 19: 431-444 [PMID: 19527988 DOI: 10.1684/ejd.2009.0739]

70 Xiong LJ, Tong Y, W�ang ZL, Mao M. Is Helicobacter pylori infection associated �ith Henoch-Schonlein purpura in Chinese children? a meta-analysis. World J Pediatr 2012; 8: 301-308 [PMID: 23151856 DOI: 10.1007/s12519-012-0373-1]

71 Zhuo WL, Zhu B, Xiang ZL, Zhuo XL, Cai L, Chen ZT. Assessment of the relationship bet�een Helicobacter pylori and lung cancer: a meta-analysis. Arch Med Res 2009; 40: 406-410 [PMID: 19766906 DOI: 10.1016/j.arcmed.2009.05.002]

72 Hashemi SH, Nadi E, Hajilooi M, Seif-Rabiei MA, Roustaei U. Relationship bet�een Helicobacter pylori infection and chronic obstructive pulmonary disease. Acta Med Iran 2011; 49: 721-724 [PMID: 22131241]

73 Koshiol J, Flores R, Lam TK, Taylor PR, W�einstein SJ, Virtamo J, Albanes D, Perez-Perez G, Caporaso NE, Blaser MJ. Helicobacter pylori seropositivity and risk of lung cancer. PLoS One 2012; 7: e32106 [PMID: 22384154 DOI: 10.1371/journal.pone.0032106]



74 Deng B, Li Y, Zhang Y, Bai L, Yang P. Helicobacter pylori infection and lung cancer: a revie� of an emerging hypothesis. Carcinogenesis 2013; 34: 1189-1195 [PMID: 23568955 DOI: 10.1093/carcin/bgt114]

75 Pellicano R, Fagoonee S. On Helicobacter pylori seropositivity in patients �ith chronic obstructive pulmonary disease. Respirology 2013; 18: 887 [PMID: 23600633 DOI: 10.1111/resp.12101]

76 Samareh Fekri M, Hashemi Bajgani SM, Rasti A, Yazdani R, Mollaie HR. Detection of helicobacter pylori in bronchoalveolar lavage of patients �ith chronic obstructive pulmonary disease by real time polymerase chain reaction. Jundishapur J Microbiol 2015; 8: e14551 [PMID: 25789128 DOI: 10.5812/jjm.14551]

77 Mendall MA, Goggin PM, Molineaux N, Levy J, Toosy T, Strachan D, Camm AJ, Northfield TC. Relation of Helicobacter pylori infection and coronary heart disease. Br Heart J 1994; 71: 437-439 [PMID: 8011406 DOI: 10.1136/hrt.71.5.437]

78 Danesh J, Peto R. Risk factors for coronary heart disease and infection �ith Helicobacter pylori: meta-analysis of 18 studies. BMJ 1998; 316: 1130-1132 [PMID: 9552950 DOI: 10.1136/bmj.316.7138.1130]

79 Franceschi F, Sepulveda AR, Gasbarrini A, Pola P, Silveri NG, Gasbarrini G, Graham DY, Genta RM. Cross-reactivity of anti-CagA antibodies �ith vascular �all antigens: possible pathogenic link bet�een Helicobacter pylori infection and atherosclerosis. Circulation 2002; 106: 430-434 [PMID: 12135941 DOI: 10.1161/ 01.CIR.0000024100.90140.19]

80 Kowalski M, Rees W�, Konturek PC, Grove R, Scheffold T, Meixner H, Brunec M, Franz N, Konturek JW�, Pieniazek P, Hahn EG, Konturek SJ, Thale J, W�arnecke H. Detection of H. pylori specific DNA in human atheromatous coronary arteries and its association to prior myocardial infarction and unstable angina. Dig Liv Dis 2002; 34: 398-402 [PMID: 121322786 DOI: 10.1016/S1590-8658(02)80036-6]

81 Tamer GS, Tengiz I, Ercan E, Duman C, Alioglu E, Turk UO. Helicobacter pylori seropositivity in patients �ith acute coronary syndromes. Dig Dis Sci 2009;2009; 54: 1253-1256 [PMID: 18770033 DOI: 10.1007/s10620-008-0482-9]

82 Christodoulou DK, Milionis HJ, Pappa P, Katsanos KH, Sigounas D, Florentin M, Elisaf M, Tsianos EV. Association of Helicobacter pylori infection �ith cardiovascular disease--is it just a myth? Eur J Intern Med 2011; 22: 191-194 [PMID: 21402252 DOI: 10.1016/j.ejim.2010.11.010]

83 Schöttker B, Adamu MA, W�eck MN, Müller H, Brenner H. Helicobacter pylori infection, chronic atrophic gastritis and major cardiovascular events: a population-based cohort study. Atherosclerosis 2012; 220: 569-574 [PMID: 22189198 DOI: 10.1016/j.atherosclerosis.2011.11.029]

84 Vahdat K, Pourbehi MR, Ostovar A, Hadavand F, Bolkheir A, Assadi M, Farrokhnia M, Nabipour I. Association of pathogen burden and hypertension: the Persian Gulf Healthy Heart Study. Am J Hypertens 2013; 26: 1140-1147 [PMID: 23744497 DOI: 10.1093/ajh/hpt083]

85 Chmiela M, Gaje�ski A, Rudnicka K. Helicobacter pylori vs coronary heart disease - searching for connections. World J Cardiol 2015; 7: 187-203 [PMID: 25914788 DOI: 10.4330/�jc.v7.i4.187]

86 Matusiak A�� Ch�łubińs��i M�� B��l M�� R��h�ińs��i T�� Ru��i�� K, Miszczyk E, W�alencka M, Strapagiel D, Gaje�ski A, Chmiela M. Putative consequences of exposure to Helicobacter pylori infec-tion in patients �ith coronary heart disease in terms of humoral immune response and inflammation. Arch Med Sci 2016; 12: 45-54 [PMID: 26925118 DOI: 10.5114/aoms.2015.50772]

87 Abdel-Hady H, Zaki A, Badra G, Lotfy M, Selmi C, Giorgini A, El-Sayed M, Badr R. Helicobacter pylori infection in hepatic encephalopathy: Relationship to plasma endotoxins and blood ammonia. Hepatol Res 2007; 37: 1026-1033 [PMID: 17610507 DOI: 10.1111/j.1872-034X.2007.00146.x]

88 Gunji T, Matsuhashi N, Sato H, Fujibayashi K, Okumura M, Sasabe N, Urabe A. Helicobacter pylori infection is significantly associated �ith metabolic syndrome in the Japanese population. Am J Gastroenterol 2008; 103: 3005-3010 [PMID: 19086952 DOI:

10.1111/j.1572-0241.2008.02151.x]89 Gunji T, Matsuhashi N, Sato H, Fujibayashi K, Okumura M,

Sasabe N, Urabe A. Helicobacter pylori infection significantly increases insulin resistance in the asymptomatic Japanese popula-tion. Helicobacter 2009; 14: 144-150 [PMID: 19751440 DOI: 10.1111/j.1523-5378.2009.00705.x]

90 El-Eshmawy MM, El-Ha�ary AK, Abdel Ga�ad SS, El-Baiomy AA. Helicobacter pylori infection might be responsible for the interconnection bet�een type 1 diabetes and autoimmune thyroid-itis. Diabetol Metab Syndr 2011; 3: 28 [PMID: 22029731 DOI: 10.1186/1758-5996-3-28]

91 Naja F, Nasreddine L, H�alla N, Moghames P, Shoaib H, Fatfat M, Sibai A, Gali-Muhtasib H. Association of H. pylori infection �ith insulin resistance and metabolic syndrome among Lebanese adults. Helicobacter 2012; 17: 444-451 [PMID: 23066847 DOI: 10.1111/j.1523-5378.2012.00970.x]

92 Ando T, Ishika�a T, Takagi T, Imamoto E, Kishimoto E, Okajima A, Uchiyama K, Handa O, Yagi N, Kokura S, Naito Y, Mizuno S, Asaka�a A, Inui A, Yoshika�a T. Impact of Helicobacter pylori eradication on circulating adiponectin in humans. Helicobacter 2013; 18: 158-164 [PMID: 23167259 DOI: 10.1111/hel.12028]

93 El-Omar EM, Oien K, El-Nujumi A, Gillen D, W�irz A, Dahill S, W�illiams C, Ardill JE, McColl KE. Helicobacter pylori infection and chronic gastric acid hyposecretion. Gastroenterology 1997; 113: 15-24 [PMID: 9207257 DOI: 10.1016/S0016-5085(97) 70075-1]

94 Shahabi S, Rasmi Y, Jazani NH, Hassan ZM. Protective effects of Helicobacter pylori against gastroesophageal reflux disease may be due to a neuroimmunological anti-inflammatory mechanism. Immunol Cell Biol 2008; 86: 175-178 [PMID: 17923849 DOI: 175-178 [PMID: 17923849 DOI:175-178 [PMID: 17923849 DOI: 10.1038/sj.icb.7100119]

95 Xie T, Cui X, Zheng H, Chen D, He L, Jiang B. Meta-analysis: eradication of Helicobacter pylori infection is associated �ith the development of endoscopic gastroesophageal reflux disease. Eur J Gastroenterol Hepatol 2013;2013; 25: 1195-1205 [PMID: 23839160 DOI: 10.1097/MEG.0b013e328363e2c]

96 Zhuo X, Zhang Y, W�ang Y, Zhuo W�, Zhu Y, Zhang X. Helicobacter pylori infection and oesophageal cancer risk: association studies via evidence-based meta-analyses. Clin Oncol (R Coll Radiol) 2008; 20: 757-762 [PMID: 18793831 DOI: 10.1016/j.clon.2008.07.005]

97 Rubenstein JH, Inadomi JM, Scheiman J, Schoenfeld P, Appelman H, Zhang M, Metko V, Kao JY. Association bet�een Helicobacter pylori and Barrett’s esophagus, erosive esophagitis, and gastro-esophageal reflux symptoms. Clin Gastroenterol Hepatol 2014; 12: 239-245 [PMID: 23988686 DOI: 10.1016/j.cgh.2013.08.029]

98 Chen Y, Blaser MJ. Inverse associations of Helicobacter pylori �ith asthma and allergy. Arch Intern Med 2007; 167: 821-827 [PMID: 17452546 DOI: 10.1086/590158]

99 Wang Y, Bi Y, Zhang L, W�ang C. Is Helicobacter pylori infection associated �ith asthma risk? A meta-analysis based on 770 cases and 785 controls. Int J Med Sci 2012; 9: 603-610 [PMID: 23028243 DOI: 10.7150/ijms.4970]

100 Wang Q, Yu C, Sun Y. The association bet�een asthma and Helicobacter pylori: a meta-analysis. Helicobacter 2013; 18: 41-53 [PMID: 23067334 DOI: 10.1111/hel.12012]

101 Zhou X, W�u J, Zhang G. Association bet�een Helicobacter pylori and asthma: a meta-analysis. Eur J Gastroenterol Hepatol 2013; 25: 460-468 [PMID: 23242126 DOI: 10.1097/MEG. 0b013e32835c280a]

102 Shiu J, Czinn SJ, Kobayashi KS, Sun Y, Blanchard TG. IRAK-M expression limits dendritic cell activation and proinflammatory cytokine production in response to Helicobacter pylori. PLoS One 2013; 8: e66914 [PMID: 23776703 DOI: 10.1371/journal.pone.0066914]

103 Karimi A, Fakhimi-Derakhshan K, Imanzadeh F, Rezaei M, Cavoshzadeh Z, Maham S. Helicobacter pylori infection and pediatric asthma. Iran J Microbiol 2013;2013; 5: 132-135 [PMID: 23825730]

104 Uemura N, Okamoto S, Yamamoto S, Matsumura N, Yamaguchi S, Yamakido M, Taniyama K, Sasaki N, Schlemper RJ.



Helicobacter pylori infection and the development of gastric cancer. N Engl J Med 2001; 345: 784-789 [PMID: 11556297 DOI: 10.1056/NEJMoa001999]

105 Pandey R, Misra V, Misra SP, D�ivedi M, Kumar A, Ti�ari BK. Helicobacter pylori and gastric cancer. Asian Pac J Cancer Prev 2010; 11: 583-588 [PMID: 21039020]

106 Venkateshwari A, Krishnaveni D, Venugopal S, Shashikumar P, Vidyasagar A, Jyothy A. Helicobacter pylori infection in relation to gastric cancer progression. Indian J Cancer 2011;2011;; 48: 94-98 [PMID: 21248438 DOI: 10.4103/0019-509X.75840]

107 Suganuma M, W�atanabe T, Yamaguchi K, Takahashi A, Fujiki H. Human gastric cancer development �ith TNF-α-inducing protein secreted from Helicobacter pylori. Cancer Lett 2012; 322: 133-138 [PMID: 22459353 DOI: 10.1016/j.canlet.2012.03.027]

108 Wang F, Meng W�, W�ang B, Qiao L. Helicobacter pylori-induced gastric inflammation and gastric cancer. Cancer Lett 2014; 345: 196-202 [PMID: 23981572 DOI: 10.1016/j.canlet.2013.08.016]

109 Asenjo LM, Gisbert JP. [Prevalence of Helicobacter pylori infection in gastric MALT lymphoma: a systematic revie�]. Rev Esp Enferm Dig 2007; 99: 398-404 [PMID: 17973584 DOI: 10.4321/S1130-01082007000700006]

110 Zullo A, Hassan C, Cristofari F, Andriani A, De Francesco V, Ierardi E, Tomao S, Stolte M, Morini S, Vaira D. Effects of Helicobacter pylori eradication on early stage gastric mucosa-associated lymphoid tissue lymphoma. Clin Gastroenterol Hepatol 2010; 8: 105-110 [PMID: 19631287 DOI: 10.1016/j.cgh.2009. 07.017]

111 Wündisch T, Dieckhoff P, Greene B, Thiede C, W�ilhelm C, Stolte M, Neubauer A. Second cancers and residual disease in patients treated for gastric mucosa-associated lymphoid tissue lymphoma by Helicobacter pylori eradication and follo�ed for 10 years. Gastroenterology 2012; 143: 936-942; quiz e13-14 [PMID: 22750463 DOI: 10.1053/j.gastro.2012.06.035]

112 Machado AM, Desler C, Bøggild S, Strickertsson JA, Friis-Hansen L, Figueiredo C, Seruca R, Rasmussen LJ. Helicobacter pylori infection affects mitochondrial function and DNA repair, thus, mediating genetic instability in gastric cells. Mech Ageing Dev 2013; 134: 460-466 [PMID: 24012633 DOI: 10.1016/j.mad.2013.08.004]

113 Leite M, Corso G, Sousa S, Milanezi F, Afonso LP, Henrique R, Soares JM, Castedo S, Carneiro F, Roviello F, Oliveira C, Seruca R. MSI phenotype and MMR alterations in familial and sporadic gas-tric cancer. Int J Cancer 2011; 128: 1606-1613 [PMID: 20533283 DOI: 10.1002/ijc.25495]

114 Figueiredo C, Garcia-Gonzalez MA, Machado JC. Molecular pathogenesis of gastric cancer. Helicobacter 2013; 18 Suppl 1: 28-33 [PMID: 24011242 DOI: 10.1111/hel.12083]

115 Nagini S. Carcinoma of the stomach: A revie� of epidemiology, pathogenesis, molecular genetics and chemoprevention. World J Gastrointest Oncol 2012; 4: 156-169 [PMID: 22844547 DOI: 10.4251/�jgo.v4.i7.156]

116 Hu B, El Hajj N, Sittler S, Lammert N, Barnes R, Meloni-Ehrig A. Gastric cancer: Classification, histology and application of molecular pathology. J Gastrointest Oncol 2012; 3: 251-261 [PMID: 22943016 DOI: 10.3978/j.issn.2078-6891.2012.021]

117 Bosman FT, Carneiro F, Hruban RH, Theise ND. W�HO classifica-tion of tumors of the digestive system. International Agency for Research on Cancer, Lyon (France): 2010

118 Lauren P. The t�o histological main types of gastric carcinoma: diffuse and so-called intestinal-type carcinoma. An attempt at a histo-clinical classification. Acta Pathol Microbiol Scand 1965; 64: 31-49 [PMID: 14320675]

119 El-Omar EM, Rabkin CS, Gammon MD, Vaughan TL, Risch HA, Schoenberg JB, Stanford JL, Mayne ST, Goedert J, Blot W�J, Fraumeni JF, Cho� W�H. Increased risk of noncardia gastric cancer associated �ith proinflammatory cytokine gene polymorphisms. Gastroenterology 2003; 124: 1193-1201 [PMID: 12730860 DOI: 10.1016/S0016-5085(03)00157-4]

120 International Agency for Research on Cancer. IARC Press; Lyon (France). 1994; 61. IARC monographs on the evaluation of

carcinogenesis risks to humans. Schistosomes, liver flukes and Helicobacter pylori

121 Miyahara R, Ni�a Y, Matsuura T, Maeda O, Ando T, Ohmiya N, Itoh A, Hirooka Y, Goto H. Prevalence and prognosis of gastric cancer detected by screening in a large Japanese population: data from a single institute over 30 years. J Gastroenterol Hepatol 2007; 22: 1435-1442 [PMID: 17573829 DOI: 10.1111/j.1440-1746.2007. 04991.x]

122 Correa P. Gastric cancer: overvie�. Gastroenterol Clin North Am 2013; 42: 211-217 [PMID: 23639637 DOI: 10.1016/j.gtc.2013.01.002]

123 Correa P, Piazuelo MB, W�ilson KT. Pathology of gastric intestinal metaplasia: clinical implications. Am J Gastroenterol 2010; 105: 493-498 [PMID: 20203636 DOI: 10.1038/ajg.2009.728]

124 Hatakeyama M. Helicobacter pylori and gastric carcinogenesis. J Gastroenterol 2009;2009; 44: 239-248 [PMID: 19271114 DOI: 10.1007/s00535-009-0014-1]

125 Chow WH, Blaser MJ, Blot W�J, Gammon MD, Vaughan TL, Risch HA, Perez-Perez GI, Schoenberg JB, Stanford JL, Rotterdam H, W�est AB, Fraumeni JF. An inverse relation bet�een cagA+ strains of Helicobacter pylori infection and risk of esophageal and gastric cardia adenocarcinoma. Cancer Res 1998; 58: 588-590 [PMID: 9485003]

126 Joossens JV, Hill MJ, Elliott P, Stamler R, Lesaffre E, Dyer A, Nichols R, Kesteloot H. Dietary salt, nitrate and stomach cancer mortality in 24 countries. European Cancer Prevention (ECP) and the INTERSALT Cooperative Research Group. Int J Epidemiol 1996; 25: 494-504 [PMID: 8671549 DOI: 10.1093/ije/25.3.494]

127 González CA, Jakszyn P, Pera G, Agudo A, Bingham S, Palli D, Ferrari P, Boeing H, del Giudice G, Plebani M, Carneiro F, Nesi G, Berrino F, Sacerdote C, Tumino R, Panico S, Berglund G, Simán H, Nyrén O, Hallmans G, Martinez C, Dorronsoro M, Barricarte A, Navarro C, Quirós JR, Allen N, Key TJ, Day NE, Linseisen J, Nagel G, Bergmann MM, Overvad K, Jensen MK, Tjonneland A, Olsen A, Bueno-de-Mesquita HB, Ocke M, Peeters PH, Numans ME, Clavel-Chapelon F, Boutron-Ruault MC, Trichopoulou A, Psaltopoulou T, Roukos D, Lund E, Hemon B, Kaaks R, Norat T, Riboli E. Meat intake and risk of stomach and esophageal adenocarcinoma �ithin the European Prospective Investigation Into Cancer and Nutrition (EPIC). J Natl Cancer Inst 2006; 98: 345-354 [PMID: 16507831 DOI: 10.1093/jnci/djj071]

128 Machado AM , Figueiredo C, Seruca R, Rasmussen LJ. Helicobacter pylori infection generates genetic instability in gastric cells. Biochim Biophys Acta 2010; 1806: 58-65 [PMID: 20122996 DOI: 10.1016/j.bbcan.2010.01.007]

129 Park DI, Park SH, Kim SH, Kim JW�, Cho YK, Kim HJ, Sohn CI, Jeon W�K, Kim BI, Cho EY, Kim EJ, Chae SW�, Sohn JH, Sung IK, Sepulveda AR, Kim JJ. Effect of Helicobacter pylori infection on the expression of DNA mismatch repair protein. Helicobacter 2005; 10: 179-184 [PMID: 15904475 DOI: 10.1111/j.1523-5378.2005.00309.x]

130 Kim JJ, Tao H, Carloni E, Leung W�K, Graham DY, Sepulveda AR. Helicobacter pylori impairs DNA mismatch repair in gastric epithelial cells. Gastroenterology 2002; 123: 542-553 [PMID: 12145807 DOI: 10.1053/gast.2002.34751]

131 Kidane D, Murphy DL, S�easy JB. Accumulation of abasic sites induces genomic instability in normal human gastric epithelial cells during Helicobacter pylori infection. Oncogenesis 2014; 3: e128 [PMID: 25417725 DOI: 10.1038/oncsis.2014.42]

132 Toller IM, Neelsen KJ, Steger M, Hartung ML, Hottiger MO, Stucki M, Kalali B, Gerhard M, Sartori AA, Lopes M, Müller A. Carcinogenic bacterial pathogen Helicobacter pylori triggers DNA double-strand breaks and a DNA damage response in its host cells. Proc Natl Acad Sci USA 2011; 108: 14944-14949 [PMID: 21896770 DOI: 10.1073/pnas.1100959108]

133 Cui Z, Chen Y, Xiao Z, Hu M, Lin Y, Chen Y, Zheng Y. Long noncoding RNAs as auxiliary biomarkers for gastric cancer screen-ing: A pooled analysis of individual studies. Oncotarget 2016; 7: 25791-25800 [PMID: 27015554 DOI: 10.18632/oncotarget.8268]

134 Cooke CL, Torres J, Solnick JV. Biomarkers of Helicobacter pylori-associated gastric cancer. Gut Microbes 2013;2013;; 4: 532-540



[PMID: 23851317 DOI: 10.4161/gmic.25720]135 Shafaghi A, Mansour-Ghanaei F, Joukar F, Sharafkhah M, Mesbah

A, Askari K, Geranmayeh S, Mehrvarz A, Souti F, Sokhanvar H, Fakhrieh S, Aminian K, Yousefi-Mashhour M, Khosh-Sorur M, Rasoulian J. Serum gastrin and the pepsinogen I/II ratio as markers for diagnosis of premalignant gastric lesions. Asian Pac J Cancer Prev 2013; 14: 3931-3936 [PMID: 23886209 DOI: 10.7314/APJCP.2013.14.6.3931]

136 Kurilovich S, Belkovets A, Reshetnikov O, Openko T, Malyutina S, Ragino Y, Scherbakova L, Leja M, Paloheimo L, Syrjänen K, Voevoda M. Stomach-specific Biomarkers (GastroPanel) Can Predict the Development of Gastric Cancer in a Caucasian Population: A Longitudinal Nested Case-Control Study in Siberia. Anticancer Res 2016; 36: 247-253 [PMID: 26722050]

137 Mizuno S, Kobayashi M, Tomita S, Miki I, Masuda A, Onoyama M, Habu Y, Inokuchi H, W�atanabe Y. Validation of the pepsinogen test method for gastric cancer screening using a follo�-up study. Gastric Cancer 2009; 12: 158-163 [PMID: 19890696 DOI: 10.1007/s10120-009-0522-y]

138 Colarossi A, Inga R, Prochazka R, Reyes U, Bussalleu A, Barúa RL. Pepsinogen and gastrin in the noninvasive diagnosis of gastric atrophy. A case-control study in Peruvian population. Rev Gastroenterol Peru 2011;2011;; 31: 110-115 [PMID: 21836650]

139 Ikeda F, Shikata K, Hata J, Fukuhara M, Hiraka�a Y, Ohara T, Mukai N, Nagata M, Yoshida D, Yonemoto K, Esaki M, Kitazono T, Kiyohara Y, Ninomiya T. Combination of Helicobacter pylori Antibody and Serum Pepsinogen as a Good Predictive Tool of Gastric Cancer Incidence: 20-Year Prospective Data From the Hisayama Study. J Epidemiol 2016; 26: 629-636 [PMID: 27265836 DOI: 10.2188/jea.JE20150258]

140 Kusters JG, van Vliet AH, Kuipers EJ. Pathogenesis of Helicobacter pylori infection. Clin Microbiol Rev 2006; 19: 449-490 [PMID: 16847081 DOI: 10.1128/CMR.00054-05]

141 Zhuo XL, W�ang Y, Zhuo W�L, Zhang XY. Possible association of Helicobacter pylori infection �ith laryngeal cancer risk: an evidence-based meta-analysis. Arch Med Res 2008; 39: 625-628 [PMID: 18662596 DOI: 10.1016/j.arcmed.2008.04.008]

142 Burduk PK. Association bet�een infection of virulence cagA gene Helicobacter pylori and laryngeal squamous cell carcinoma. Med Sci Monit 2013; 19: 584-591 [PMID: 23860397 DOI: 10.12659/MSM.889011]

143 Machida-Montani A, Sasazuki S, Inoue M, Natsuka�a S, Shaura K, Koizumi Y, Kasuga Y, Hanaoka T, Tsugane S. Atrophic gastritis, Helicobacter pylori, and colorectal cancer risk: a case-control study. Helicobacter 2007; 12: 328-332 [PMID: 17669106 DOI: 10.1111/j.1523-5378.2007.00513.x]

144 Lin YL, Chiang JK, Lin SM, Tseng CE. Helicobacter pylori infec-tion concomitant �ith metabolic syndrome further increase risk of colorectal adenomas. World J Gastroenterol 2010; 16: 3841-3846 [PMID: 20698048 DOI: 10.3748/�jg.v16.i30.3841]

145 Wu Q, Yang ZP, Xu P, Gao LC, Fan DM. Association bet�een Helicobacter pylori infection and the risk of colorectal neoplasia: a systematic revie� and meta-analysis. Colorectal Dis 2013; 15: e352-e364 [PMID: 23672575 DOI: 10.1111/codi.12284]

146 Kountouras J, Kapetanakis N, Zavos C, Romiopoulos I. Impact of Helicobacter pylori infection on normal colorectal mucosa, adenomatous polyps and adenocarcinoma sequence. Colorectal Dis 2014; 16: 390-391 [PMID: 23869417 DOI: 10.1111/codi.12356]

147 Xuan SY, Xin YN, Chen AJ, Dong QJ, Qiang X, Li N, Zheng MH, Guan HS. Association bet�een the presence of H pylori in the liver and hepatocellular carcinoma: a meta-analysis. World J Gastroenterol 2008; 14: 307-312 [PMID: 18186573 DOI: 10.3748/�jg.v14.i2.307]

148 Tu QV, Okoli AS, Kovach Z, Mendz GL. Hepatocellular carcinoma: prevalence and molecular pathogenesis of Helicobacter spp. Future Microbiol 2009; 4: 1283-1301 [PMID: 19995189 DOI: 10.2217/fmb.09.90]

149 Esmat G, El-Bendary M, Zakarya S, Ela MA, Zalata K. Role of Helicobacter pylori in patients �ith HCV-related chronic hepatitis and cirrhosis �ith or �ithout hepatocellular carcinoma: possible

association �ith disease progression. J Viral Hepat 2012; 19: 473-479 [PMID: 22676359 DOI: 10.1111/j.1365-2893.2011.01567.x]

150 Rabelo-Gonçalves EM, Sgardioli IC, Lopes-Cendes I, Escanhoela CA, Almeida JR, Zeitune JM. Improved detection of Helicobacter pylori DNA in formalin-fixed paraffin-embedded (FFPE) tissue of patients �ith hepatocellular carcinoma using laser capture microdissection (LCM). Helicobacter 2013;2013; 18: 244-245 [PMID: 23350684 DOI: 10.1111/hel.12040]

151 Raderer M, W�rba F, Kornek G, Maca T, Koller DY, W�einlaender G, Hejna M, Scheithauer W�. Association bet�een Helicobacter pylori infection and pancreatic cancer. Oncology 1998;1998;; 55: 16-19 [PMID: 9428370 DOI: 10.1159/000011830]

152 Stolzenberg-Solomon RZ, Blaser MJ, Limburg PJ, Perez-Perez G, Taylor PR, Virtamo J, Albanes D. Helicobacter pylori seropositiv-ity as a risk factor for pancreatic cancer. J Natl Cancer Inst 2001; 93: 937-941 [PMID: 11416115 DOI: 10.1093/jnci/93.12.937]

153 Trikudanathan G, Philip A, Dasanu CA, Baker W�L. Association bet�een Helicobacter pylori infection and pancreatic cancer. A cumulative meta-analysis. JOP 2011; 12: 26-31 [PMID: 21206097 DOI: 10.6092/1590-8577/3379]

154 Polyzos SA, Kountouras J, Zavos C, Deretzi G. The association bet�een Helicobacter pylori infection and insulin resistance: a systematic revie�. Helicobacter 2011;2011; 16: 79-88 [PMID: 21435084 DOI: 10.1111/j.1523-5378.2011.00822.x]

155 Michaud DS. Role of bacterial infections in pancreatic cancer. Carcinogenesis 2013;2013; 34: 2193-2197 [PMID: 23843038 DOI: 10.1093/carcin/bgt249]

156 Risch HA. Pancreatic cancer: Helicobacter pylori colonization, N-nitrosamine exposures, and ABO blood group. Mol Carcinog 2012; 51: 109-118 [PMID: 22162235 DOI: 10.1002/mc.20826]

157 Bessède E , Staedel C, Acuña Amador LA, Nguyen PH, Chambonnier L, Hatakeyama M, Belleannée G, Mégraud F, Varon C. Helicobacter pylori generates cells �ith cancer stem cell properties via epithelial-mesenchymal transition-like changes. Oncogene 2014; 33: 4123-4131 [PMID: 24096479 DOI: 10.1038/onc.2013.380]

158 Chattopadhyay S, Patra R, Chatterjee R, De R, Alam J, Ramamurthy T, Cho�dhury A, Nair GB, Berg DE, Mukhopadhyay AK. Distinct repeat motifs at the C-terminal region of CagA of Helicobacter pylori strains isolated from diseased patients and asymptomatic individuals in W�est Bengal, India. Gut Pathog 2012; 4: 4 [PMID: 22631862 DOI: 10.1186/1757-4749-4-4]

159 Jones KR, Joo YM, Jang S, Yoo YJ, Lee HS, Chung IS, Olsen CH, W�hitmire JM, Merrell DS, Cha JH. Polymorphism in the CagA EPIYA motif impacts development of gastric cancer. J Clin Microbiol 2009; 47: 959-968 [PMID: 19158258 DOI: 10.1128/JCM.02330-08]

160 Kawai M, Furuta Y, Yahara K, Tsuru T, Oshima K, Handa N, Takahashi N, Yoshida M, Azuma T, Hattori M, Uchiyama I, Kobayashi I. Evolution in an oncogenic bacterial species �ith extreme genome plasticity: Helicobacter pylori East Asian genomes. BMC Microbiol 2011; 11: 104 [PMID: 21575176 DOI: 10.1186/1471-2180-11-104]

161 Vaziri F, Peerayeh SN, Alebouyeh M, Maghsoudi N, Azimzadeh P, Siadat SD, Zali MR. Novel effects of Helicobacter pylori CagA on key genes of gastric cancer signal transduction: a comparative transfection study. Pathog Dis 2015; 73: pii: ftu021 [PMID: 25743471 DOI: 10.1093/femspd/ftu021]

162 Fajardo CA, Quiroga AJ, Coronado A, Labrador K, Acosta N, Delgado P, Jaramillo C, Bravo MM. CagA EPIYA polymorphisms in Colombian Helicobacter pylori strains and their influence on disease-associated cellular responses. World J Gastrointest Oncol 2013; 5: 50-59 [PMID: 23671731 DOI: 10.4251/�jgo.v5.i3.50]

163 Batista SA, Rocha GA, Rocha AM, Saraiva IE, Cabral MM, Oliveira RC, Queiroz DM. Higher number of Helicobacter pylori CagA EPIYA C phosphorylation sites increases the risk of gastric cancer, but not duodenal ulcer. BMC Microbiol 2011; 11: 61 [PMID: 21435255 DOI: 10.1186/1471-2180-11-61]

164 Basso D, Zambon CF, Letley DP, Stranges A, Marchet A, Rhead JL, Schiavon S, Guariso G, Ceroti M, Nitti D, Rugge M, Plebani M,



Atherton JC. Clinical relevance of Helicobacter pylori cagA and vacA gene polymorphisms. Gastroenterology 2008;2008; 135: 91-99 [PMID: 18474244 DOI: 10.1053/j.gastro.2008.03.041]

165 Yamaoka Y, Kodama T, Gutierrez O, Kim JG, Kashima K, Graham DY. Relationship bet�een Helicobacter pylori iceA, cagA, and vacA status and clinical outcome: studies in four different countries. J Clin Microbiol 1999; 37: 2274-2279 [PMID: 10364597]

166 Zhang XS, Tegtmeyer N, Traube L, Jindal S, Perez-Perez G, Sticht H, Backert S, Blaser MJ. A specific A/T polymorphism in W�estern tyrosine phosphorylation B-motifs regulates Helicobacter pylori CagA epithelial cell interactions. PLoS Pathog 2015; 11: e1004621 [PMID: 25646814 DOI: 10.1371/journal.ppat.1004621]

167 Reyes-Leon A, Atherton JC, Argent RH, Puente JL, Torres J. Heterogeneity in the activity of Mexican Helicobacter pylori strains in gastric epithelial cells and its association �ith diversity in the cagA gene. Infect Immun 2007; 75: 3445-3454 [PMID: 17438024 DOI: 10.1128/IAI.01951-06]

168 Argent RH, Kidd M, O�en RJ, Thomas RJ, Limb MC, Atherton JC. Determinants and consequences of different levels of CagA phosphorylation for clinical isolates of Helicobacter pylori. Gastroenterology 2004; 127: 514-523 [PMID: 15300584 DOI: 10.1053/j.gastro.2004.06.006]

169 Bridge DR, Merrell DS. Polymorphism in the Helicobacter pylori CagA and VacA toxins and disease. Gut Microbes 2013;2013;; 4: 101-117 [PMID: 23380646 DOI: 10.4161/gmic.23797]

170 Jones KR, Jang S, Chang JY, Kim J, Chung IS, Olsen CH, Merrell DS, Cha JH. Polymorphisms in the intermediate region of VacA impact Helicobacter pylori-induced disease development. J Clin Microbiol 2011; 49: 101-110 [PMID: 21084502 DOI: 10.1128/ JCM.01782-10]

171 Latifi-Navid S, Mohammadi S, Maleki P, Zahri S, Yazdanbod A, Siavoshi F, Massarrat S. Helicobacter pylori vacA d1/-i1 genotypes and geographic differentiation bet�een high and lo� incidence areas of gastric cancer in Iran. Arch Iran Med 2013; 16: 330-337 [PMID: 23725065 DOI: 013166/AIM.005]

172 Ogiwara H, Sugimoto M, Ohno T, Vilaichone RK, Mahachai V, Graham DY, Yamaoka Y. Role of deletion located bet�een the intermediate and middle regions of the Helicobacter pylori vacA gene in cases of gastroduodenal diseases. J Clin Microbiol 2009; 47: 3493-3500 [PMID: 19726606 DOI: 10.1128/JCM.00887-09]

173 Sheu BS, Odenbreit S, Hung KH, Liu CP, Sheu SM, Yang HB, W�u JJ. Interaction bet�een host gastric Sialyl-Le�is X and H. pylori SabA enhances H. pylori density in patients lacking gastric Le�is B antigen. Am J Gastroenterol 2006;2006; 101: 36-44 [PMID: 16405531 DOI: 10.1111/j.1572-0241.2006.00358.x]

174 Senkovich OA, Yin J, Ekshyyan V, Conant C, Traylor J, Adegboyega P, McGee DJ, Rhoads RE, Slepenkov S, Testerman TL. Helicobacter pylori AlpA and AlpB bind host laminin and influence gastric inflammation in gerbils. Infect Immun 2011; 79: 3106-3116 [PMID: 21576328 DOI: 10.1128/IAI.01275-10]

175 Snelling WJ, Moran AP, Ryan KA, Scully P, McGourty K, Cooney JC, Annuk H, O’Toole PW�. HorB (HP0127) is a gastric epithelial cell adhesin. Helicobacter 2007;2007; 12: 200-209 [PMID: 17492999 DOI: 10.1111/j.1523-5378.2007.00499.x]

176 Torres LE, Melián K, Moreno A, Alonso J, Sabatier CA, Hernández M, Bermúdez L, Rodríguez BL. Prevalence of vacA, cagA and babA2 genes in Cuban Helicobacter pylori isolates. World J Gastroenterol 2009; 15: 204-210 [PMID: 19132771 DOI: 10.3748/�jg.v15.i2.204]

177 Zambon CF, Navaglia F, Basso D, Rugge M, Plebani M. Helicobacter pylori babA2, cagA, and s1 vacA genes �ork synergistically in causing intestinal metaplasia. J Clin Pathol 2003; 56: 287-291 [PMID: 12663641 DOI: 10.1136/jcp.56.4.287]

178 Dossumbekova A, Prinz C, Mages J, Lang R, Kusters JG, Van Vliet AH, Reindl W�, Backert S, Saur D, Schmid RM, Rad R. Helicobacter pylori HopH (OipA) and bacterial pathogenicity: genetic and functional genomic analysis of hopH gene polymor-phisms. J Infect Dis 2006; 194: 1346-1355 [PMID: 17054063 DOI: 10.1086/508426]

179 Jia ZF, Zhang SL, Cao XY, Zhou BS, Jiang J. Interaction bet�een Helicobacter pylori and host genetic variants in gastric carcinogen-esis. Future Oncol 2016; 12: 2127-2134 [PMID: 27324311 DOI: 10.2217/fon-2016-0233]

180 Dowling JK, Mansell A. Toll-like receptors: the s�iss army knife of immunity and vaccine development. Clin Transl Immunology 2016; 5: e85 [PMID: 27350884 DOI: 10.1038/cti.2016.22]

181 Leifer CA, Medvedev AE. Molecular mechanisms of regulation of Toll-like receptor signaling. J Leukoc Biol 2016; 100: 927-941 [PMID: 27343013 DOI: 10.1189/jlb.2MR0316-117RR]

182 Castaño-Rodríguez N, Kaakoush NO, Goh KL, Fock KM, Mitchell HM. The role of TLR2, TLR4 and CD14 genetic polymorphisms in gastric carcinogenesis: a case-control study and meta-analysis. PLoS One 2013; 8: e60327 [PMID: 23565226 DOI: 10.1371/journal.pone.0060327]

183 Castaño-Rodríguez N, Kaakoush NO, Mitchell HM. Pattern-recognition receptors and gastric cancer. Front Immunol 2014; 5: 336 [PMID: 25101079 DOI: 10.3389/fimmu.2014.00336]

184 Pimentel-Nunes P, Afonso L, Lopes P, Roncon-Albuquerque R, Gonçalves N, Henrique R, Moreira-Dias L, Leite-Moreira AF, Dinis-Ribeiro M. Increased expression of toll-like receptors (TLR) 2, 4 and 5 in gastric dysplasia. Pathol Oncol Res 2011; 17: 677-683 [PMID: 21455638 DOI: 10.1007/s12253-011-9368-9]

185 Chochi K, Ichikura T, Kinoshita M, Majima T, Shinomiya N, Tsujimoto H, Ka�abata T, Sugasa�a H, Ono S, Seki S, Mochizuki H. Helicobacter pylori augments gro�th of gastric cancers via the lipopolysaccharide-toll-like receptor 4 path�ay �hereas its lipopolysaccharide attenuates antitumor activities of human mononuclear cells. Clin Cancer Res 2008; 14: 2909-2917 [PMID: 18483357 DOI: 10.1158/1078-0432.CCR-07-4467]

186 Bagheri N, Azadegan-Dehkordi F, Sanei H, Taghikhani A, Rahimian G, Salimzadeh L, Hashemzadeh-Chaleshtori M, Rafieian-kopaei M, Shirzad M, Shirzad H. Associations of a TLR4 single-nucleotide polymorphism �ith H. pylori associated gastric diseases in Iranian patients. Clin Res Hepatol Gastroenterol 2014; 38: 366-371 [PMID: 24508388 DOI: 10.1016/j.clinre.2013.12.004]

187 Zhou Q, W�ang C, W�ang X, W�u X, Zhu Z, Liu B, Su L. Association bet�een TLR4 (+896A/G and +1196C/T) polymorphisms and gastric cancer risk: an updated meta-analysis. PLoS One 2014; 9: e109605 [PMID: 25290654 DOI: 10.1371/journal.pone.0109605]

188 Smith SM, Moran AP, Duggan SP, Ahmed SE, Mohamed AS, W�indle HJ, O’Neill LA, Kelleher DP. Tribbles 3: a novel regulator of TLR2-mediated signaling in response to Helicobacter pylori lipopolysaccharide. J Immunol 2011; 186: 2462-2471 [PMID: 21220698 DOI: 10.4049/jimmunol.1000864]

189 Pugin J, Heumann ID, Tomasz A, Kravchenko VV, Akamatsu Y, Nishijima M, Glauser MP, Tobias PS, Ulevitch RJ. CD14 is a pattern recognition receptor. Immunity 1994; 1: 509-516 [PMID: 7534618 DOI: 10.1016/1074-7613(94)90093-0]

190 White JR, W�inter JA, Robinson K. Differential inflammatory response to Helicobacter pylori infection: etiology and clinical outcomes. J Inflamm Res 2015; 8: 137-147 [PMID: 26316793 DOI: 10.2147/JIR.S64888]

191 Wang J, Guo X, Yu S, Song J, Zhang J, Cao Z, W�ang J, Liu M, Dong W�. Association bet�een CD14 gene polymorphisms and cancer risk: a meta-analysis. PLoS One 2014; 9: e100122 [PMID: 24978812 DOI: 10.1371/journal.pone.0100122]

192 Zhang DE, Hetherington CJ, Tan S, Dziennis SE, Gonzalez DA, Chen HM, Tenen DG. Sp1 is a critical factor for the monocytic specific expression of human CD14. J Biol Chem 1994; 269: 11425-11434 [PMID: 7512565]

193 Tong X, Li Z, Fu X, Zhou K, W�u Y, Zhang Y, Fan H. The associa-tion bet�een CD14-260C/T polymorphism and malignant tumor risk: a meta-analysis of 5,603 participants. Tumour Biol 2014; 35: 8707-8713 [PMID: 24870592 DOI: 10.1007/s13277-014-2040-8]

194 Franchi L, W�arner N, Viani K, Nuñez G. Function of Nod-like receptors in microbial recognition and host defense. Immunol Rev 2009; 227: 106-128 [PMID: 19120480 DOI: 10.1111/j.1600-065X.2008.00734.x]

195 Moreira LO, Zamboni DS. NOD1 and NOD2 Signaling in



Infection and Inflammation. Front Immunol 2012; 3: 328 [PMID: 23162548 DOI: 10.3389/fimmu.2012.00328]

196 Hess J, Angel P, Schorpp-Kistner M. AP-1 subunits: quarrel and harmony among siblings. J Cell Sci 2004; 117: 5965-5973 [PMID: 15564374 DOI: 10.1242/jcs.01589]

197 Allison CC, Kufer TA, Kremmer E, Kaparakis M, Ferrero RL. Helicobacter pylori induces MAPK phosphorylation and AP-1 acti-vation via a NOD1-dependent mechanism. J Immunol 2009; 183: 8099-8109 [PMID: 20007577 DOI: 10.4049/jimmunol.0900664]

198 Allison CC, Ferrand J, McLeod L, Hassan M, Kaparakis-Liaskos M, Grubman A, Bhathal PS, Dev A, Sievert W�, Jenkins BJ, Ferrero RL. Nucleotide oligomerization domain 1 enhances IFN-γ signal-ing in gastric epithelial cells during Helicobacter pylori infection and exacerbates disease severity. J Immunol 2013; 190: 3706-3715 [PMID: 23460743 DOI: 10.4049/jimmunol.12005]

199 Grubman A, Kaparakis M, Viala J, Allison C, Badea L, Karrar A, Boneca IG, Le Bourhis L, Reeve S, Smith IA, Hartland EL, Philpott DJ, Ferrero RL. The innate immune molecule, NOD1, regulates direct killing of Helicobacter pylori by antimicrobial peptides. Cell Microbiol 2010; 12: 626-639 [PMID: 20039881 DOI: 10.1111/j.1462-5822.2009.01421.x]

200 Rosenstiel P, Hellmig S, Hampe J, Ott S, Till A, Fischbach W�, Sahly H, Lucius R, Fölsch UR, Philpott D, Schreiber S. Influence of polymorphisms in the NOD1/CARD4 and NOD2/CARD15 genes on the clinical outcome of Helicobacter pylori infection. Cell Microbiol 2006; 8: 1188-1198 [PMID: 16819970 DOI: 10.1111/j.1462-5822.2006.00701.x]

201 Kim DJ, Park JH, Franchi L, Backert S, Núñez G. The Cag patho-genicity island and interaction bet�een TLR2/NOD2 and NLRP3 regulate IL-1β production in Helicobacter pylori infected dendritic cells. Eur J Immunol 2013; 43: 2650-2658 [PMID: 23818043 DOI: 10.1002/eji.201243281]

202 Wang P, Zhang L, Jiang JM, Ma D, Tao HX, Yuan SL, W�ang YC, W�ang LC, Liang H, Zhang ZS, Liu CJ. Association of NOD1 and NOD2 genes polymorphisms �ith Helicobacter pylori related gastric cancer in a Chinese population. World J Gastroenterol 2012; 18: 2112-2120 [PMID: 22563200 DOI: 10.3748/�jg.v18.i17.2112]

203 Companioni O, Bonet C, Muñoz X, W�eiderpass E, Panico S, Tumino R, Palli D, Agnoli C, Vineis P, Boutron-Ruault MC, Racine A, Clavel-Chapelon F, Travis RC, Kha� KT, Riboli E, Murphy N, Vergnaud AC, Trichopoulou A, Benetou V, Trichopoulos D, Lund E, Johansen D, Lindkvist B, Johansson M, Sund M, Ardanaz E, Sánchez-Cantalejo E, Huerta JM, Dorronsoro M, Ramón Quirós J, Tjonneland A, Mortensen LM, Overvad K, Chang-Claude J, Rizzato C, Boeing H, Bueno-de-Mesquita HB, Siersema P, Peeters PH, Numans ME, Carneiro F, Licaj I, Freisling H, Sala N, González CA. Polymorphisms of Helicobacter pylori signaling path�ay genes and gastric cancer risk in the European Prospective Investigation into Cancer-Eurgast cohort. Int J Cancer 2014; 134: 92-101 [PMID: 23824692 DOI: 10.1002/ijc.28357]

204 Ramis IB, Vianna JS, Gonçalves CV, von Groll A, Dellagostin OA, da Silva PE. Polymorphisms of the IL-6, IL-8 and IL-10 genes and the risk of gastric pathology in patients infected �ith Helicobacter pylori. J Microbiol Immunol Infect 2015; 48: pii: S1684-1182(15)00721-5 [PMID: 25888319 DOI: 10.1016/j.jmii. 2015.03.002]

205 Melo Barbosa HP, Martins LC, Dos Santos SE, Demachki S, Assumpção MB, Aragão CD, de Oliveira Corvelo TC. Interleukin-1 and TNF-alpha polymorphisms and Helicobacter pylori in a Brazilian Amazon population. World J Gastroenterol 2009; 15: 1465-1471 [PMID: 19322919 DOI: 10.3748/�jg.v15.i12.1465]

206 El-Omar EM, Carrington M, Cho� W�H, McColl KE, Bream JH, Young HA, Herrera J, Lisso�ska J, Yuan CC, Rothman N, Lanyon G, Martin M, Fraumeni JF, Rabkin CS. Interleukin-1 polymor-phisms associated �ith increased risk of gastric cancer. Nature 2000; 404: 398-402 [PMID: 10746728 DOI: 10.1038/35006081]

207 Hwang IR, Kodama T, Kikuchi S, Sakai K, Peterson LE, Graham DY, Yamaoka Y. Effect of interleukin 1 polymorphisms on gastric

mucosal interleukin 1beta production in Helicobacter pylori infec-tion. Gastroenterology 2002;2002; 123: 1793-1803 [PMID: 12454835 DOI: 10.1053/gast.2002.37043]

208 Perri F, Terracciano F, Gentile M, Merla A, Scimeca D, Zullo A. Role of interleukin polymorphisms in gastric cancer: “Pros and cons”. World J Gastrointest Oncol 2010; 2: 265-271 [PMID: 21160639 DOI: 10.4251/�jgo.v2.i6.265]

209 Con SA, Takeuchi H, Con-Chin GR, Con-Chin VG, Yasuda N, Con-W�ong R. Role of bacterial and genetic factors in gastric cancer in Costa Rica. World J Gastroenterol 2009; 15: 211-218 [PMID: 19132771 DOI: 10.3748/�jg.v15.i2.211]

210 Caleman Neto A, Rasmussen LT, de Labio RW�, de Queiroz VF, Smith Mde A, Viani GA, Payão SL. Gene polymorphism of interleukin 1 and 8 in chronic gastritis patients infected �ith Helicobacter pylori. J Venom Anim Toxins Incl Trop Dis 2014; 20: 17 [PMID: 24803922 DOI: 10.1186/1678-9199-20-17]

211 Al-Moundhri MS, Al-Nabhani M, Al-Bahrani B, Burney IA, Al-Madhani A, Ganguly SS, Al-Yahyaee SA, Grant CS. Interleukin-1beta gene (IL-1B) and interleukin 1 receptor antago-nist gene (IL-1RN) polymorphisms and gastric cancer risk in an Omani Arab population. Gastric Cancer 2006; 9: 284-290 [PMID: 17235630 DOI: 10.1007/s10120-006-0392-5]

212 Ramani T, Auletta CS, W�einstock D, Mounho-Zamora B, Ryan PC, Salcedo TW�, Bannish G. Cytokines: The Good, the Bad, and the Deadly. Int J Toxicol 2015;; 34: 355-365 [PMID: 26015504 DOI: 10.1177/1091581815584918]

213 Brenner D, Blaser H, Mak TW�. Regulation of tumour necrosis fac-tor signalling: live or let die. Nat Rev Immunol 2015; 15: 362-374 [PMID: 26008591 DOI: 10.1038/nri3834]

214 Shibata J, Goto H, Arisa�a T, Ni�a Y, Hayaka�a T, Nakayama A, Mori N. Regulation of tumour necrosis factor (TNF) induced apop-tosis by soluble TNF receptors in Helicobacter pylori infection. Gut 1999; 45: 24-31 [PMID: 10369700 DOI: 10.1136/gut.45.1.24]

215 Yea SS, Yang YI, Jang W�H, Lee YJ, Bae HS, Paik KH. Association bet�een TNF-alpha promoter polymorphism and Helicobacter pylori cagA subtype infection. J Clin Pathol 2001; 54: 703-706 [PMID: 11533078 DOI: 10.1136/jcp.54.9.703]

216 Sun X, Xu Y, W�ang L, Zhang F, Zhang J, Fu X, Jing T, Han J. Association bet�een TNFA Gene Polymorphisms and Helicobacter pylori Infection: A Meta-Analysis. PLoS One 2016; 11: e0147410 [PMID: 26815578 DOI: 10.1371/journal.pone.0147410]

217 Qi M, Liu DM, Pan LL, Lin YX. Interleukin-10 gene -592C& gt; A polymorphism and susceptibility to gastric cancer. Genet Mol Res 2014; 13: 8954-8961 [PMID: 25366786 DOI: 10.4238/2014.October.31.10]

218 Ni P, Xu H, Xue H, Lin B, Lu Y. A meta-analysis of interleu-kin-10-1082 promoter polymorphism associated �ith gastric cancer risk. DNA Cell Biol 2012; 31: 582-591 [PMID: 22335769 DOI: 10.1089/dna.2011.1440]

219 Kim J, Cho YA, Choi IJ, Lee YS, Kim SY, Shin A, Cho SJ, Kook MC, Nam JH, Ryu KW�, Lee JH, Kim YW�. Effects of interleukin-10 polymorphisms, Helicobacter pylori infection, and smoking on the risk of noncardia gastric cancer. PLoS One 2012; 7: e29643 [PMID: 22235320 DOI: 10.1371/journal.pone.0029643]

220 Ohyauchi M, Imatani A, Yonechi M, Asano N, Miura A, Iijima K, Koike T, Sekine H, Ohara S, Shimosega�a T. The polymorphism interleukin 8 -251 A/T influences the susceptibility of Helicobacter pylori related gastric diseases in the Japanese population. Gut 2005; 54: 330-335 [PMID: 15710978 DOI: 10.1136/gut.2003.033050]

221 Zhao F, Zhu H, Huang M, Yi C, Huang Y. The 765G& gt; C polymorphism in the cyclooxygenase-2 gene and gastric cancer risk: an update by meta-analysis. Asian Pac J Cancer Prev 2014; 15: 2863-2868 [PMID: 24761915 DOI: 10.7314/APJCP.2014.15.6.2863]

222 Li Y, Dai L, Zhang J, W�ang P, Chai Y, Ye H, Zhang J, W�ang K. Cyclooxygenase-2 polymorphisms and the risk of gastric cancer in various degrees of relationship in the Chinese Han population. Oncol Lett 2012; 3: 107-112 [PMID: 22740864 DOI: 10.3892/ol.2011.426]

223 Zheng C, Huang D, Liu L, Björkholm M, Holm G, Yi Q, Sundblad A. Cytotoxic T-lymphocyte antigen-4 microsatellite polymorphism



is associated �ith multiple myeloma. Br J Haematol 2001; 112: 216-218 [PMID: 11167807 DOI: 10.1046/j.1365-2141.2001.02552.x]

224 Sharpe AH, Freeman GJ. The B7-CD28 superfamily. Nat Rev Immunol 2002;2002; 2: 116-126 [PMID: 11910893 DOI: 10.1038/nri727]

225 Ueda H , Ho�son JM, Esposito L, He�ard J, Snook H, Chamberlain G, Rainbo� DB, Hunter KM, Smith AN, Di Genova G, Herr MH, Dahlman I, Payne F, Smyth D, Lo�e C, T�ells RC, Ho�lett S, Healy B, Nutland S, Rance HE, Everett V, Smink LJ, Lam AC, Cordell HJ, W�alker NM, Bordin C, Hulme J, Motzo C, Cucca F, Hess JF, Metzker ML, Rogers J, Gregory S, Allahabadia A, Nithiyananthan R, Tuomilehto-W�olf E, Tuomilehto J, Bingley

P, Gillespie KM, Undlien DE, Rønningen KS, Guja C, Ionescu-Tî��viş�� C�� v�� DA�� M�x��ll A�� C��s�� DJ�� s�� CC�� Franklyn JA, Clayton DG, Peterson LB, W�icker LS, Todd JA, Gough SC. Association of the T-cell regulatory gene CTLA4 �ith susceptibility to autoimmune disease. Nature 2003; 423: 506-511 [PMID: 12724780 DOI: 10.1038/nature01621]

226 Cheng TY, Lin JT, Chen LT, Shun CT, W�ang HP, Lin MT, W�ang TE, Cheng AL, W�u MS. Association of T-cell regulatory gene polymorphisms �ith susceptibility to gastric mucosa-associated lymphoid tissue lymphoma. J Clin Oncol 2006;2006; 24: 3483-3489 [PMID: 16849765 DOI: 10.1200/JCO.2005.05.5434]

P- Reviewer: Cover TL, Vaziri F S- Editor: Gong ZM L- Editor: A E- Editor: Liu W�X



© 2017 Baishideng Publishing Group Inc. All rights reserved.

Published by Baishideng Publishing Group Inc8226 Regency Drive, Pleasanton, CA 94588, USA

Telephone: +1-925-223-8242Fax: +1-925-223-8243

E-mail: [email protected] Desk: http://www.wjgnet.com/esps/helpdesk.aspx

http://www.wjgnet.com

I S S N 1 0 0 7 - 9 3 2 7

9 7 7 1 0 07 9 3 2 0 45

0 9

host pathogen interactions in helicobacter pylori related gastric … · 2017-04-29 · h. pylori...

Documents